Author: "ORS PACA" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"ORS PACA"' showing total 835 results

Start Over Author "ORS PACA"

835 results on '"ORS PACA"'

1. Vaccine Attitudes and Practices of Hospital Specialists (SPECIVAC)

Author: Innovative clinical research network in vaccinology (I-REIVAC) and Observatoire Régionale de la santé ORS-PACA
Published: 2021

2. Relation entre déficit cognitif et niveau de dépendance dans la population de personnes âgées. PREMAP 1992

Author: Observatoire Régional de la Santé - ORS PACA, Obadia, Y., Rotily, M., Guélain, J., Loundou, D.A., Bensadoun, D., Degrand-Guillaud, Anne, Simonetto, I., Ali Chérif, A., Poncet, M., Observatoire Régional de la Santé - ORS PACA, Obadia, Y., Rotily, M., Guélain, J., Loundou, D.A., Bensadoun, D., Degrand-Guillaud, Anne, Simonetto, I., Ali Chérif, A., and Poncet, M.
Published: 1998

3. The PREMAP Study: prevalence and risk factors of dementia and clinically diagnosed Alzheimer's disease in Provence, France. Prevalence of Alzheimer's Disease in Provence.

Author: Observatoire Régional de la Santé - ORS PACA, Obadia, Y, Rotily, M, Degrand-Guillaud, Anne, Guelain, J, Ceccaldi, M, Severo, C, Poncet, M, Alperovitch, A, Observatoire Régional de la Santé - ORS PACA, Obadia, Y, Rotily, M, Degrand-Guillaud, Anne, Guelain, J, Ceccaldi, M, Severo, C, Poncet, M, and Alperovitch, A
Abstract: The PREMAP Study investigated the prevalence and risk factors of dementia and Alzheimer's Disease (AD) in a random sample of 1062 residents 70 year old or more, living in south-eastern France (private homes and institutions). All persons living in institutions for the elderly (n = 258) and community dwellers (n = 804) scoring less than 24 points on the MMSE (18.4%) were invited to undergo a medical evaluation at home by a qualified neurologist using the CERAD battery. We found 177 cases of dementia (9.2%), including 82 cases of AD (5.5%). Prevalence of AD increased significantly with age and was higher among women (OR: 4.24) and persons with no formal educational level (OR: 2.47). While a MMS score less than 24 was more frequent among persons with a foreign native language (OR: 3.05), the OR and AD was not significantly associated with native language. The proportion of AD among persons suffering from senile dementia was 45% among elderly living in institutions and 69% among those living in the community. Prevalence rates in south-eastern France are similar to the average rates for Europe. This study underlines the need to investigate the relationships between native language, MMSE and AD on the one hand, and the link between a low MMSE score and institutionalisation of patients suffering from AD on the other.
Published: 1997

4. Méthodologie d'enquête sur la prévalence de la maladie d'Alzheimer dans les Bouches du Rhône

Author: Observatoire Régional de la Santé - ORS PACA, INSERM - Unité 169, Institut de santé des armées du Pharo - Médecine des collectivités, Degrand-Guillaud, Anne, Obadia, Y., Guélain, J., Observatoire Régional de la Santé - ORS PACA, INSERM - Unité 169, Institut de santé des armées du Pharo - Médecine des collectivités, Degrand-Guillaud, Anne, Obadia, Y., and Guélain, J.
Abstract: Cette enquête transversale a pour objectif de mesurer la prévalence des démences séniles et de la maladie d'Alzheimer sur le département des Bouches du Rhône (Marseille, France). Un échantillon représentatif de 3000 personnes âgées de plus de 70 ans a été sélectionné. La méthodologie utilisée est celle d'un sondage aléatoire en deux phases dont le détail est explicité dans l'article .
Published: 1991

5. MOTIVAC-MATER-Confiance

Author: CRES PACA Marseille, Institut de Recherche en Santé Publique, France, Hospital St. Joseph, Marseille, France, Hôpital Sainte-Musse CH Toulon, Université de Sherbrooke, and Pierre Verger, Head of ORS PACA (Observatoire Régional de la Santé - Provence-Alpes-Côte-d'Azur)
Published: 2023

6. Attitude toward a COVID-19 vaccine in France. Different factors according to age (COVID-19 vaccine: The French population’s attitude)

Author: Alleaume, Caroline, Peretti-Watel, Patrick, Verger, Pierre, Launay, Odile, Grp, Coconel, Raude, Jocelyn, Santé publique France - French National Public Health Agency [Saint-Maurice, France], Vecteurs - Infections tropicales et méditerranéennes (VITROME), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées [Brétigny-sur-Orge] (IRBA), Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille] (ORS PACA), CIC Cochin Pasteur (CIC 1417), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôtel-Dieu-Groupe hospitalier Broca-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), The COCONEL Group, École des Hautes Études en Santé Publique [EHESP] (EHESP), Centre de recherche en économie et management (CREM), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS)-Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS)-Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Vecteurs - Infections tropicales et méditerranéennes (VITROME), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées [Brétigny-sur-Orge] (IRBA)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées [Brétigny-sur-Orge] (IRBA)-Groupe d'Etude des Méthodes de l'Analyse Sociologique de la Sorbonne (GEMASS), Fondation Maison des sciences de l'homme (FMSH)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Fondation Maison des sciences de l'homme (FMSH)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)- Southeastern Health Regional Observatory (ORS Paca)-Inserm CIC 1417, Université Paris, Faculté de Médecine Paris Descartes, AP-HP, Hôpital Cochin, and Département des sciences humaines et sociales (SHS)
Subjects: Health (social science), Vaccination, Enquête COCONEL, Covid 19, Refus, Elderly, Attitude, Enquêtes de cohorte, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, France, Population âgée, Geriatrics and Gerontology, COCONEL cohort surveys, Gerontology
Abstract: International audience; Like in many countries, the French health authorities are pinning their hopes on vaccination to stop the spread of the COVID-19 pandemic. However, this requires the public to get the vaccine. Based on six COCONEL surveys carried out during and after the lockdown among the general French adult population, which aimed to explore life conditions during this period and individual perceptions of the situation, this paper aims to investigate the acceptability of a putative vaccine against COVID-19 among the French population, and more specifically to compare attitudes among the elderly, who are more vulnerable to the disease, with those of younger people. Out of the 8,036 respondents, 27.5% declared that they would refuse the vaccine if it were available. Among the age groups of particular interest, 29.2% of people aged 18–64 said they would refuse the vaccine, compared to 12.4% of respondents aged 65 or over. For both groups, this refusal rate fluctuated depending on the date of the survey, gender, household composition, level of household income, and uptake of the last flu vaccine. In conclusion, more attention should be paid to elderly people, as they were more likely to report hostility toward vaccination in general. Finally, considering that several vaccines are now available, further studies should be done to study vaccine uptake in relation to the vaccine offered.; La campagne vaccinale contre la COVID-19 est une priorité sanitaire. Toutefois, l’adhésion de la population française à cette vaccination est un élément clé de sa réussite. À la lumière de six enquêtes COCONEL réalisées en population générale adulte pendant et après le confinement dans l’objectif de documenter les conditions de vie des Français pendant cette période ainsi que leur perception des mesures mises en place par les autorités, cet article propose d’analyser l’intention de se faire vacciner des Français à l’égard d’une vaccination contre la COVID-19, selon l’âge. Plus spécifiquement, l’intention des personnes âgées de 65 ans et plus, particulièrement vulnérables face à cette maladie, comparativement aux personnes plus jeunes. Parmi les 8 036 répondants, 27,5 % refuseraient ce vaccin s’il était disponible ; 29,2 % des 18-64 ans contre 12,4 % des 65 ans et plus. Quel que soit l’âge, ce refus de vaccination varie selon la date d’enquête, mais aussi selon le genre, la composition du foyer, le niveau de revenus, ainsi que la pratique vaccinale antérieure contre la grippe saisonnière. En conclusion, une attention particulière devra être portée aux personnes âgées de 65 ans et plus qui sont plus enclines à manifester une hostilité à la vaccination en général. Enfin, la mise sur le marché de différents vaccins devrait encourager à poursuivre les analyses de l’adhésion vaccinale au regard du vaccin proposé.
Published: 2022

7. The positive effect of workplace accommodations on the continued employment of cancer survivors five years after diagnosis

Author: Caroline Alleaume, Alain Paraponaris, Marc-Karim Bendiane, Anne-Déborah Bouhnik, Patrick Peretti-Watel, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), ORS PACA, Aix-Marseille Sciences Economiques (AMSE), École des hautes études en sciences sociales (EHESS)-Aix Marseille Université (AMU)-École Centrale de Marseille (ECM)-Centre National de la Recherche Scientifique (CNRS), Vecteurs - Infections tropicales et méditerranéennes (VITROME), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées (IRBA), Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille] (ORS PACA), The VICAN survey was funded by the National Institute of Cancer (INCa), « Contrat de recherche et développement No. 05-2011 ». However, this institute did not fund this study. This work was supported by French National Research Agency grant ANR-17-EURE-0020., ANR-17-EURE-0020,AMSE (EUR),Aix-Marseille School of Economics(2017), COMBE, Isabelle, Aix-Marseille School of Economics - - AMSE (EUR)2017 - ANR-17-EURE-0020 - EURE - VALID, and Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées [Brétigny-sur-Orge] (IRBA)
Subjects: Adult, Employment, Male, medicine.medical_specialty, Time Factors, Adolescent, Cancer survivors, Psychological intervention, Return to work, Young Adult, 03 medical and health sciences, 0302 clinical medicine, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Continued employment, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Neoplasms, Surveys and Questionnaires, Humans, Medicine, [SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology, Workplace accommodations, 030212 general & internal medicine, [SHS.ECO] Humanities and Social Sciences/Economics and Finance, Workplace, [SDV.MP.VIR] Life Sciences [q-bio]/Microbiology and Parasitology/Virology, [SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases, Receipt, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, business.industry, Nursing research, Cancer, Middle Aged, [SHS.ECO]Humanities and Social Sciences/Economics and Finance, medicine.disease, [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Oncology, 030220 oncology & carcinogenesis, Family medicine, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, Propensity score matching, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Female, France, [SDV.MP.BAC] Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, business, VICAN5, [SDV.MP.PAR] Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology
Abstract: International audience; Purpose To address the gap highlighted in the literature on the effect of professional interventions to facilitate continued employment, this study aims to evaluate the effect of workplace accommodations on the continued employment 5 years after a cancer diagnosis. Methods This study is based on VICAN5, a French survey conducted in 2015-2016 to examine the living conditions of cancer survivors 5 years after diagnosis. Two subsamples, one with and one without workplace accommodations, were matched using a propensity score to control for the individual, professional, and medical characteristics potentially associated with receipt of workplace accommodations. Results The study sample was composed of 1514 cancer survivors aged 18-54 and employed as salaried at diagnosis. Among them, 61.2% received workplace accommodations within 5 years after diagnosis: 35.5% received a modified workstation, 41.5% received a modified schedule, and 49.2% received reduced hours. After matching, receipt of workplace accommodations appeared to improve the continued employment rate 5 years after cancer diagnosis from 77.8% to 95.0%. Conclusions Receipt of workplace accommodations strongly increases the continued employment of cancer survivors 5 years after diagnosis. More research is needed to better understand the differences in receipt of workplace accommodations along with the related selection effect.
Published: 2020

8. Incidence of PTSD in the French population a month after the COVID-19 pandemic-related lockdown: evidence from a national longitudinal survey

Author: Alleaume, Caroline, Peretti-Watel, Patrick, Beck, François, Leger, Damien, Vaiva, Guillaume, Verger, Pierre, Raude, Jocelyn, Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille] (ORS PACA), Vecteurs - Infections tropicales et méditerranéennes (VITROME), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées [Brétigny-sur-Orge] (IRBA), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Sommeil-Vigilance-Fatigue et Santé Publique (VIFASOM (URP_7330)), Institut de Recherche Biomédicale des Armées [Brétigny-sur-Orge] (IRBA)-Université Paris Cité (UPCité), Hôpital Hôtel-Dieu [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Lille Neurosciences & Cognition - U 1172 (LilNCog), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), École des Hautes Études en Santé Publique [EHESP] (EHESP), The COCONEL Group, Centre de recherche en économie et management (CREM), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS)-Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS)-Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Vecteurs - Infections tropicales et méditerranéennes (VITROME), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées [Brétigny-sur-Orge] (IRBA)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées [Brétigny-sur-Orge] (IRBA)-Groupe d'Etude des Méthodes de l'Analyse Sociologique de la Sorbonne (GEMASS), Fondation Maison des sciences de l'homme (FMSH)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Fondation Maison des sciences de l'homme (FMSH)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)- Southeastern Health Regional Observatory (ORS Paca)-Inserm CIC 1417, Université Paris, Faculté de Médecine Paris Descartes, AP-HP, Hôpital Cochin, ANR-20-COVI-0035-01, COCONEL Group: Patrick Peretti-Watel, Valérie Seror, Sébastien Cortaredona, Odile Launay, Jocelyn Raude, Pierre Verger, Caroline Alleaume, Lisa Fressard, Guillaume Vaiva, François Beck, Stéphane Legleye, Damien Léger, Olivier L'Haridon, Jeremy K Ward, ANR-20-COVI-0035,COCONEL,COronavirus et CONfinement : Enquête Longitudinale(2020), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées (IRBA), Institut de Recherche Biomédicale des Armées (IRBA)-Université Paris Cité (UPCité), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées (IRBA)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées (IRBA)-Groupe d'Etude des Méthodes de l'Analyse Sociologique de la Sorbonne (GEMASS), and EHESP, SCD
Subjects: [SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases, Adult, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, Depression, Incidence, [SDV.MHEP.PSM] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, Public Health, Environmental and Occupational Health, PTSD, Anxiety, PCL-5, Stress Disorders, Post-Traumatic, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, Communicable Disease Control, Lockdown, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Humans, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Longitudinal Studies, COCONEL cohort surveys, Covid-19, Pandemics, Aged
Abstract: Background In view of experts’ warnings about the potential negative mental health consequences of the sudden nationwide lockdowns implemented in many countries to limit the spread of the COVID-19 pandemic, we sought to study the incidence of posttraumatic stress disorder (PTSD) after traumatic events related to this unprecedented lockdown in the French general population. Methods This longitudinal study among adults (aged =18) consisted of two surveys: the first during the last days of the lockdown and the second a month later. We estimated PTSD incidence with the PCL-5 and ran multiple Poisson regression models to identify factors associated with PTSD. Results Among the 1736 participants, 30.1% reported at least one traumatic event. PTSD incidence was 17.5% (95% confidence interval CI = 15.7–19.3). It was higher in participants who reported multiple traumatic events, who had high COVID-19-related media use, who had general anxiety disorder (GAD-7) during the lockdown, and who had GAD, depression (PHQ-9), or sleep problems 1 month later. In addition, 43.1% of people with PTSD reported suicidal thoughts. Conclusions These results should help clinicians to target people who are at high risk of developing PTSD after a pandemic-related lockdown and could benefit from preventive measures. Collaboration between the media and mental health professionals could be envisioned to inform the population about care resources. Follow-up recommendations should also be disseminated to general practitioners to facilitate PTSD screening and ensure that they are aware of the appropriate management.
Published: 2022

9. The French public's attitudes to a future COVID-19 vaccine: The politicization of a public health issue

Author: Jeremy K. Ward, Caroline Alleaume, Patrick Peretti-Watel, Valérie Seror, Sébastien Cortaredona, Odile Launay, Jocelyn Raude, Pierre Verger, François Beck, Stéphane Legleye, Olivier L'Haridon, Jeremy Ward, Groupe d'Etude des Méthodes de l'Analyse Sociologique de la Sorbonne (GEMASS), Fondation Maison des sciences de l'homme (FMSH)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Vecteurs - Infections tropicales et méditerranéennes (VITROME), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées [Brétigny-sur-Orge] (IRBA), CIC Cochin Pasteur (CIC 1417), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôtel-Dieu-Groupe hospitalier Broca-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), École des Hautes Études en Santé Publique [EHESP] (EHESP), Département des sciences humaines et sociales (SHS), Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille] (ORS PACA), ORS PACA, Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Centre de recherche en économie et management (CREM), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS), Centre National de la Recherche Scientifique, CNRSAgence Nationale de la Recherche, ANR: ANR-20-COVI-0035-01, ANR-20-COVI-0035,COCONEL,COronavirus et CONfinement : Enquête Longitudinale(2020), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées (IRBA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université de Paris (UP)-Groupe hospitalier Broca-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôtel-Dieu-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU), Institut de Recherche Biomédicale des Armées (IRBA)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU), CCSD, Accord Elsevier, and COronavirus et CONfinement : Enquête Longitudinale - - COCONEL2020 - ANR-20-COVI-0035 - COVID-19 - VALID
Subjects: Male, Health Knowledge, Attitudes, Practice, Health (social science), Public opinion, 0302 clinical medicine, Pandemic, 030212 general & internal medicine, [SHS.ECO] Humanities and Social Sciences/Economics and Finance, media_common, education.field_of_study, Politics, Vaccination, Age Factors, Hesitancy, Public relations, Middle Aged, 16. Peace & justice, [SHS.ECO]Humanities and Social Sciences/Economics and Finance, 3. Good health, Female, Ideology, France, 0305 other medical science, Adult, medicine.medical_specialty, COVID-19 Vaccines, Adolescent, media_common.quotation_subject, Short Communication, Population, Health(social science), 03 medical and health sciences, Young Adult, Sex Factors, History and Philosophy of Science, Political science, medicine, Humans, education, Pandemics, Aged, 030505 public health, business.industry, SARS-CoV-2, Public health, COVID-19, Partisanship, Quarter (United States coin), Coronavirus, Cross-Sectional Studies, Socioeconomic Factors, Political system, business
Abstract: As Covid-19 spreads across the world, governments turn a hopeful eye towards research and development of a vaccine against this new disease. But it is one thing to make a vaccine available, and it is quite another to convince the public to take the shot, as the precedent of the 2009 H1N1 influenza illustrated. In this paper, we present the results of four online surveys conducted in April 2020 in representative samples of the French population 18 years of age and over (N = 5018). These surveys were conducted during a period when the French population was on lockdown and the daily number of deaths attributed to the virus reached its peak. We found that if a vaccine against the new coronavirus became available, almost a quarter of respondents would not use it. We also found that attitudes to this vaccine were correlated significantly with political partisanship and engagement with the political system. Attitudes towards this future vaccine did not follow the traditional mapping of political attitudes along a Left-Right axis. The rift seems to be between people who feel close to governing parties (Centre, Left and Right) on the one hand, and, on the other, people who feel close to Far-Left and Far-Right parties as well as people who do not feel close to any party. We draw on the French sociological literature on ordinary attitudes to politics to discuss our results as well as the cultural pathways via which political beliefs can affect perceptions of vaccines during the COVID-19 pandemic., Highlights • Almost a quarter of the French population would not get vaccinated against COVID-19. • Attitudes are correlated with political partisanship and engagement with politics. • Attitudes do not follow the traditional separation between Left-wing and Right-wing. • Refusal is associated with proximity radical parties and to abstention.
Published: 2020

10. A future vaccination campaign against COVID-19 at risk of vaccine hesitancy and politicisation

Author: Sébastien Cortaredona, Odile Launay, Lisa Fressard, Patrick Peretti-Watel, Valérie Seror, Pierrea Verger, Stéphane Legleye, Jocelyn Raude, François Beck, Jeremy K. Ward, Damien Leger, Olivier l'Haridon, l'Observatoire français des drogues et des toxicomanies (OFDT), OFDT, The COCONEL Group, Vecteurs - Infections tropicales et méditerranéennes (VITROME), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées (IRBA), Institut National de la Santé et de la Recherche Médicale (INSERM), École des Hautes Études en Santé Publique [EHESP] (EHESP), Département des sciences humaines et sociales (SHS), Centre de recherche en économie et management (CREM), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS)-Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS)-Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Vecteurs - Infections tropicales et méditerranéennes (VITROME), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées (IRBA)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées (IRBA)-Groupe d'Etude des Méthodes de l'Analyse Sociologique de la Sorbonne (GEMASS), Fondation Maison des sciences de l'homme (FMSH)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Fondation Maison des sciences de l'homme (FMSH)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)- Southeastern Health Regional Observatory (ORS Paca)-Inserm CIC 1417, Université Paris, Faculté de Médecine Paris Descartes, AP-HP, Hôpital Cochin, Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille] (ORS PACA), Centre de Recherche Psychotropes, Santé Mentale, Société (CESAMES), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Normandie Université (NU)-Normandie Université (NU)-Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS), Sommeil-Vigilance-Fatigue et Santé Publique (VIFASOM - EA 7330), Université Paris Descartes - Paris 5 (UPD5)-Institut de Recherche Biomédicale des Armées (IRBA), CERMES3 - Centre de recherche Médecine, sciences, santé, santé mentale, société (CERMES3 - UMR 8211 / U988 / UM 7), École des hautes études en sciences sociales (EHESS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), EHESP, SCD, Centre National de la Recherche Scientifique (CNRS)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-Centre National de la Recherche Scientifique (CNRS)-Université de Rennes 1 (UR1), Normandie Université (NU)-Normandie Université (NU)-Centre de recherche en épidémiologie et santé des populations (CESP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Vecteurs - Infections tropicales et méditerranéennes (VITROME), Normandie Université (NU)-Normandie Université (NU), Institut de Recherche Biomédicale des Armées (IRBA)-Université Paris Descartes - Paris 5 (UPD5), Institut de Recherche Biomédicale des Armées (IRBA)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU), Institut de Recherche Biomédicale des Armées (IRBA)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées (IRBA)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Groupe d'Etude des Méthodes de l'Analyse Sociologique de la Sorbonne (GEMASS), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées [Brétigny-sur-Orge] (IRBA), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées [Brétigny-sur-Orge] (IRBA)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées [Brétigny-sur-Orge] (IRBA)-Groupe d'Etude des Méthodes de l'Analyse Sociologique de la Sorbonne (GEMASS), Université Paris Descartes - Paris 5 (UPD5)-Institut de Recherche Biomédicale des Armées [Brétigny-sur-Orge] (IRBA), and ANR-21-CO16-0005,Coscreen,Définition et évaluation de stratégies de dépistage du Covid screening dans des contextes variés, à partir de données de contact empiriques(2021)
Subjects: Health Knowledge, Attitudes, Practice, COVID-19 Vaccines, Coronavirus disease 2019 (COVID-19), [SHS.SOCIO] Humanities and Social Sciences/Sociology, Pneumonia, Viral, Article, 03 medical and health sciences, Betacoronavirus, 0302 clinical medicine, Vaccination Refusal, Political science, Environmental health, Humans, 030212 general & internal medicine, Vaccine hesitancy, Pandemics, ComputingMilieux_MISCELLANEOUS, 030304 developmental biology, 0303 health sciences, Vaccines, [SHS.SOCIO]Humanities and Social Sciences/Sociology, Immunization Programs, SARS-CoV-2, Vaccination, Politics, COVID-19, Viral Vaccines, Patient Acceptance of Health Care, 3. Good health, Infectious Diseases, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Immunization, France, Coronavirus Infections
Abstract: International audience
Published: 2020
Full Text: View/download PDF

11. Who are the PLWH who might refuse to participate in HIV cure-related clinical trials with treatment interruption?

Author: Protière, Christel, Fiorentino, Marion, Sow, Abdourahmane, Préau, Marie, Mora, Marion, Fressard, Lisa, Meyer, Laurence, Lelièvre, Jean-Daniel, Lambotte, Olivier, Spire, Bruno, Suzan-Monti, Marie, Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille] (ORS PACA), Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Groupe de Recherche en Psychologie Sociale (GRePS), Université Lumière - Lyon 2 (UL2), Vecteurs - Infections tropicales et méditerranéennes (VITROME), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées (IRBA), Institut Hospitalier Universitaire Méditerranée Infection (IHU Marseille), Sexualité et soins (Genre, Sexualité, Santé) (CESP - INSERM U1018 - Equipe 7), Centre de recherche en épidémiologie et santé des populations (CESP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Université Paris-Est Créteil Val-de-Marne - Faculté de médecine (UPEC Médecine), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Immunologie antivirale systémique et cérébrale, Université Paris-Sud - Paris 11 (UP11)-IFR93-Institut National de la Santé et de la Recherche Médicale (INSERM), ORS PACA, Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées [Brétigny-sur-Orge] (IRBA), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), and COMBE, Isabelle
Subjects: [SDV.MP.VIR] Life Sciences [q-bio]/Microbiology and Parasitology/Virology, [SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, [SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology, [SDV.MP.BAC] Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, [SDV.MP.PAR] Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system
Abstract: International audience; Achieving a HIV cure has become a research priority. As any improvement of knowledge, which could help scientists design new HIV cure-related clinical trials (HCRCT) depends on the risks potential participants are willing to accept, it is important to understand who will agree or refuse to participate and in which proportions. By providing insights into factors associated with reluctance toward HCRCT participation, our results may help clinicians in patient recruitment.
Published: 2020

12. Anxiety, depression and sleep problems: a second wave of COVID-19

Author: Patrick Peretti-Watel, Caroline Alleaume, Damien Léger, François Beck, Pierre Verger, Valérie Seror, Sébastien Cortaredona, Odile Launay, Jocelyn Raude, Lisa Fressard, Stéphane Legleye, Olivier L’Haridon, Jeremy Ward, Vecteurs - Infections tropicales et méditerranéennes (VITROME), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées [Brétigny-sur-Orge] (IRBA), Institut Hospitalier Universitaire Méditerranée Infection (IHU Marseille), Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille] (ORS PACA), The COCONEL Group, Centre de recherche en économie et management (CREM), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS)-Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS)-Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Vecteurs - Infections tropicales et méditerranéennes (VITROME), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées [Brétigny-sur-Orge] (IRBA)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées [Brétigny-sur-Orge] (IRBA)-Groupe d'Etude des Méthodes de l'Analyse Sociologique de la Sorbonne (GEMASS), Fondation Maison des sciences de l'homme (FMSH)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Fondation Maison des sciences de l'homme (FMSH)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)- Southeastern Health Regional Observatory (ORS Paca)-Inserm CIC 1417, Université Paris, Faculté de Médecine Paris Descartes, AP-HP, Hôpital Cochin, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Unité des Virus Emergents (UVE), École des Hautes Études en Santé Publique [EHESP] (EHESP), Département des sciences humaines et sociales (SHS), ANR-20-COVI-0035,COCONEL,COronavirus et CONfinement : Enquête Longitudinale(2020), Institut de Recherche Biomédicale des Armées (IRBA)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU), Centre National de la Recherche Scientifique (CNRS)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-Centre National de la Recherche Scientifique (CNRS)-Université de Rennes 1 (UR1), Normandie Université (NU)-Normandie Université (NU)-Centre de recherche en épidémiologie et santé des populations (CESP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Vecteurs - Infections tropicales et méditerranéennes (VITROME), Institut de Recherche Biomédicale des Armées (IRBA)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées (IRBA)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Groupe d'Etude des Méthodes de l'Analyse Sociologique de la Sorbonne (GEMASS), Aix Marseille Université (AMU)-Institut de Recherche pour le Développement (IRD)-Institut National de la Santé et de la Recherche Médicale (INSERM), COMBE, Isabelle, Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées (IRBA), and Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées (IRBA)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées (IRBA)-Groupe d'Etude des Méthodes de l'Analyse Sociologique de la Sorbonne (GEMASS)
Subjects: medicine.medical_specialty, History, lcsh:RC435-571, [SDV]Life Sciences [q-bio], Clinical Neurology, law.invention, 03 medical and health sciences, 0302 clinical medicine, law, lcsh:Psychiatry, Quarantine, Pandemic, Correspondence, medicine, 030212 general & internal medicine, Psychiatry, China, Depression (differential diagnoses), Public health, COVID-19, medicine.disease, anxiety, Mental health, 3. Good health, [SDV] Life Sciences [q-bio], Psychiatry and Mental health, Neurology, depression, Anxiety, Neurology (clinical), medicine.symptom, 030217 neurology & neurosurgery, mental health, Psychological trauma
Abstract: International audience; During the early spring of 2020, as the COVID-19 (coronavirus disease 2019) pandemic spread across the globe like a viral tsunami, many countries urgently implemented unprecedented mitigation measures to slow it down, following the example of China, where the disease first emerged at the end of 2019. As a result, more than 3 billion unprepared people worldwide had to cope with living under stringent lockdown measures for weeks or months, depending on the country. Together with the deaths of hundreds of thousands of people from this disease, a frightening emotional shock has touched populations everywhere around the planet. Millions have lost their jobs, others have had their personal lives changed drastically; the elderly, for example, have sometimes been isolated from any visits. To our knowledge, no guidelines to prevent psychological trauma have been proposed, even for the most vulnerable individuals. Nonetheless, before this crisis began, several experts had warned about the potential impact of such measures on the populations’ mental health, based on previous experiences of quarantine, as summarised in a review published, as this pandemic reached Europe and before any lockdowns.1 This warning was confirmed a few days later by the publication of a nationwide study conducted in China reporting that the quarantine triggered a wide variety of psychological disorders.2 In France, one of the hardest hit countries in Europe, a nationwide lockdown started on 17 March and lasted till 11 May. Public health authorities made daily recommendations on how to prevent COVID-19 infection with almost no specific advice on psychological prevention.
Published: 2020

13. Poor sleep associated with overuse of media during the COVID-19 lockdown

Author: Léger, Damien, Beck, François, Fressard, Lisa, Verger, Pierre, Peretti-Watel, Patrick, Seror, Valérie, Cortaredona, Sébastien, Launay, Odile, Raude, Jocelyn, Legleye, Stéphane, L’Haridon, Olivier, Ward, Jeremy, Sommeil-Vigilance-Fatigue et Santé Publique (VIFASOM - EA 7330), Institut de Recherche Biomédicale des Armées (IRBA)-Université Paris Descartes - Paris 5 (UPD5), The COCONEL Group, Centre de Recherche Psychotropes, Santé Mentale, Société (CESAMES), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Vecteurs - Infections tropicales et méditerranéennes (VITROME), Institut de Recherche Biomédicale des Armées (IRBA)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU), Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille] (ORS PACA), Unité des Virus Emergents (UVE), Aix Marseille Université (AMU)-Institut de Recherche pour le Développement (IRD)-Institut National de la Santé et de la Recherche Médicale (INSERM), École des Hautes Études en Santé Publique [EHESP] (EHESP), Département des sciences humaines et sociales (SHS), Centre de recherche en économie et management (CREM), Centre National de la Recherche Scientifique (CNRS)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-Centre National de la Recherche Scientifique (CNRS)-Université de Rennes 1 (UR1), Normandie Université (NU)-Normandie Université (NU)-Centre de recherche en épidémiologie et santé des populations (CESP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Vecteurs - Infections tropicales et méditerranéennes (VITROME), Institut de Recherche Biomédicale des Armées (IRBA)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées (IRBA)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Groupe d'Etude des Méthodes de l'Analyse Sociologique de la Sorbonne (GEMASS), Fondation Maison des sciences de l'homme (FMSH)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Fondation Maison des sciences de l'homme (FMSH)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)- Southeastern Health Regional Observatory (ORS Paca)-Inserm CIC 1417, Université Paris, Faculté de Médecine Paris Descartes, AP-HP, Hôpital Cochin, COMBE, Isabelle, Université Paris Descartes - Paris 5 (UPD5)-Institut de Recherche Biomédicale des Armées (IRBA), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées (IRBA), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS)-Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS)-Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Vecteurs - Infections tropicales et méditerranéennes (VITROME), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées (IRBA)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées (IRBA)-Groupe d'Etude des Méthodes de l'Analyse Sociologique de la Sorbonne (GEMASS), Université Paris Descartes - Paris 5 (UPD5)-Institut de Recherche Biomédicale des Armées [Brétigny-sur-Orge] (IRBA), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées [Brétigny-sur-Orge] (IRBA), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées [Brétigny-sur-Orge] (IRBA)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées [Brétigny-sur-Orge] (IRBA)-Groupe d'Etude des Méthodes de l'Analyse Sociologique de la Sorbonne (GEMASS), and ANR-20-COVI-0035,COCONEL,COronavirus et CONfinement : Enquête Longitudinale(2020)
Subjects: 2019-20 coronavirus outbreak, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), [SDV]Life Sciences [q-bio], MEDLINE, Clinical Neurology, 03 medical and health sciences, 0302 clinical medicine, Physiology (medical), Medicine, 030212 general & internal medicine, AcademicSubjects/MED00385, Intensive care medicine, Letter to the Editor, ComputingMilieux_MISCELLANEOUS, AcademicSubjects/SCI01870, business.industry, Poor sleep, [SDV] Life Sciences [q-bio], COVID-19 lockdown, Neurology (clinical), business, Sleep, 030217 neurology & neurosurgery, AcademicSubjects/MED00370
Abstract: International audience
Published: 2020

14. What is the effect of self-identified HIV activism in willingness to participate in HIV cure-related clinical trials? Results from the ANRS-APSEC study

Author: Olivier Lambotte, Mohamed Mimi, Lisa Fressard, Luis Sagaon-Teyssier, Janine Barbot, Marion Fiorentino, Michael P Arnold, Cécile Goujard, Sylvie Fainzang, Laurence Meyer, Marie Préau, Bruno Spire, Marie Suzan-Monti, Christel Protière, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Vecteurs - Infections tropicales et méditerranéennes (VITROME), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées [Brétigny-sur-Orge] (IRBA), Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille] (ORS PACA), AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), service de Médecine Interne et d'Immunologie Clinique [AP-HP Hôpital Bicêtre], Université Paris-Sud - Paris 11 (UP11)-Hôpital Bicêtre, Assistance Publique - Hôpitaux de Paris (AP-HP), Centre d'étude des mouvements sociaux (CEMS), École des hautes études en sciences sociales (EHESS)-Centre National de la Recherche Scientifique (CNRS), CERMES3 - Centre de recherche Médecine, sciences, santé, santé mentale, société (CERMES3 - UMR 8211 / U988 / UM 7), École des hautes études en sciences sociales (EHESS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Groupe de Recherche en Psychologie Sociale (GRePS), Université Lumière - Lyon 2 (UL2), ORS PACA, Epidémiologie et Sciences Sociales Appliquées à l'Innovation Médicale, Université de la Méditerranée - Aix-Marseille 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de Recherche Biomédicale des Armées (IRBA)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Descartes - Paris 5 (UPD5)-École des hautes études en sciences sociales (EHESS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées (IRBA), CERMES3 - Centre de recherche Médecine, sciences, santé, santé mentale, société (CERMES3 - UM 7 (UMR 8211 / U988)), Centre de recherche Médecine, Science, Santé et Société (CERMES), Université Paris-Sud - Paris 11 (UP11)-École des hautes études en sciences sociales (EHESS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U912 INSERM - Aix Marseille Univ - IRD), and COMBE, Isabelle
Subjects: 0301 basic medicine, cure research, Epidemiology, Immunology, Human immunodeficiency virus (HIV), medicine.disease_cause, Microbiology, activism, 03 medical and health sciences, 0302 clinical medicine, cure trial, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Virology, Medicine, [SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology, 030212 general & internal medicine, Hiv services, 10. No inequality, Original Research, [SDV.MP.VIR] Life Sciences [q-bio]/Microbiology and Parasitology/Virology, [SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, business.industry, Public Health, Environmental and Occupational Health, virus diseases, HIV, Odds ratio, willingness to participate in clinical trials, [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, QR1-502, Confidence interval, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, 3. Good health, Clinical trial, 030104 developmental biology, Infectious Diseases, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, France, [SDV.MP.BAC] Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, Public aspects of medicine, RA1-1270, business, Psychosocial, Viral load, [SDV.MP.PAR] Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology, Demography
Abstract: Objectives Enrolling people living with HIV with undetectable viral load into HIV cure-related clinical trials (HCRCT) is challenging. Few data are currently available about the individual factors that influence willingness to participate in HCRCT (WPHCRCT). We hypothesised that WPHCRCT would be more frequent among people living with HIV considering themselves HIV activists. The objective of this study was to investigate the individual characteristics associated with both WPHCRCT and self-identification as an HIV activist. Methods The study enrolled 195 long-term ART-treated and virologically suppressed people living with HIV, followed-up in 19 French HIV services, 2016–2017. A Bayesian model averaging approach was used to assess correlates of both outcomes i.e. WPHCRCT and self-identified HIV activism. Results WPHCRCT was reported by 43% of participants and was positively associated with self-identification as an HIV activist (adjusted odds ratio [aOR] 2.90 95% confidence interval [CI] 2.17–3.63], P0.75, indicating strong evidence. Conclusions WPHCRCT is strongly related to HIV activism, and also to positive psychosocial characteristics as a person living with HIV, especially regarding relationships with others. The desire to contribute to the fight against HIV for the sake of the HIV community and society should be taken into account to improve participation in upcoming HCRCT.
Published: 2019

15. Sleep disturbances in HIV-HCV coinfected patients

Author: Costa, Marie, Rojas, Teresa Rojas, Lacoste, Denis, Villes, Virginie, Aumaitre, Hugues, Protopopescu, Camelia, Yaya, Issifou, Wittkop, Linda, Krause, Jessica, Salmon-Céron, Dominique, Marcellin, Fabienne, Sogni, Philippe, Carrieri, Maria, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille] (ORS PACA), Epidémiologie, santé publique et développement, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR99-ISPED, Centre d'études et de recherche sur les services de santé et la qualité de vie (CEReSS), Aix Marseille Université (AMU), Service des maladies infectieuses CHU Perpignan, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U912 INSERM - Aix Marseille Univ - IRD), Epidémiologie et Biostatistique [Bordeaux], Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Services des Maladies Infectieuses et Tropicales [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Saint-Antoine [APHP], Service de médecine interne et centre de référence des maladies rares [CHU Cochin], CHU Cochin [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Service d'hépatologie médicale [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Cochin [AP-HP], and ORS PACA
Subjects: [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, ComputingMilieux_MISCELLANEOUS
Abstract: International audience
Published: 2019

16. Opioid Analgesics Prescription to End-of-Life Cancer Patients: Characteristics, Attitudes, and Practices of French General Practitioners

Author: Julien Mancini, Asmaa Janah, Aline Sarradon-Eck, Pierre Verger, Anne-Déborah Bouhnik, Patrick Peretti-Watel, Marc-Karim Bendiane, Dominique Rey, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille] (ORS PACA), Biostatistique et technologies de l'information et de la communication (BioSTIC) - [Hôpital de la Timone - APHM] (BiosTIC ), Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Vecteurs - Infections tropicales et méditerranéennes (VITROME), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées [Brétigny-sur-Orge] (IRBA), Institut Hospitalier Universitaire Méditerranée Infection (IHU Marseille), The study was funded by the Directorate for Research, Studies, Assessment, and Statistics of Ministry of Health (French acronym DREES), the French Ministry of Social Affairs and Health, the National Institute for prevention and health education (French acronym INPES), the National Institute for Health and Medical Research (French acronym Inserm), and the IReSP. The DREES and INPES, funding agencies of the study, played a supporting role in the study design and result analysis, the ORS PACA-UMR-SESSTIM ensured scientific coordination of the study., Dupuis, Christine, Service Biostatistique et Technologies de l’Information et de la Communication [AP-HM Hôpital de la Timone] (BioSTIC), Hôpital de la Timone [CHU - APHM] (TIMONE), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées (IRBA), and Institut de Recherche Biomédicale des Armées (IRBA)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)
Subjects: Adult, Male, medicine.medical_specialty, Health Knowledge, Attitudes, Practice, Attitude of Health Personnel, education, Patient characteristics, 03 medical and health sciences, 0302 clinical medicine, General Practitioners, Neoplasms, medicine, gender, Humans, cancer, pain, 030212 general & internal medicine, Medical prescription, General Nursing, end-of-life care, Aged, general practitioners (GPs), Terminal Care, business.industry, Cancer, opioids, General Medicine, Pain management, Middle Aged, medicine.disease, 3. Good health, Analgesics, Opioid, Anesthesiology and Pain Medicine, Cross-Sectional Studies, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, 030220 oncology & carcinogenesis, Family medicine, Health Care Surveys, Female, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, France, Opioid analgesics, business, End-of-life care
Abstract: International audience; BACKGROUND:Pain management, especially at the end of life, varies depending on the prescriber's characteristics and attitudes. Little is known about the practices of general practitioners (GPs) regarding end-of-life management for patients with cancer.OBJECTIVES:To provide an overview of the characteristics associated with GPs' attitudes and practices regarding opioids prescribing and to explore GPs' perceived role and difficulties in managing end-of-life care for patients with cancer.DESIGN:A cross-sectional study (December 2015 to March 2016). Subjects and Analyses: Data were collected from a representative sample of 376 GPs in southeastern France recruited to participate in a survey on medical practices and opinions regarding cancer patient management. Descriptive analyses and multivariate logistic regressions were conducted to study the characteristics, attitudes, and practices associated with GPs' opioids prescribing attitudes.RESULTS:Almost 97% of GPs stated that they prescribe opioids to end-of-life cancer patients. Among these, 77% said that they prescribe opioids on their own initiative, while 23% declared doing so in coordination with a specialist team. Female GPs, GPs working in solo practices, and GPs reporting more difficulties in managing end-of-life cancer patients were significantly less likely to prescribe opioids on their own initiative.CONCLUSION:Our results suggest that GPs' characteristics and practices influence the prescribing attitudes at the end of life. Given the dearth of studies on this topic, further research is recommended to better understand the impact of GPs' characteristics on their prescriptive attitudes. The possible interactions between patients' and physicians' characteristics-in particular gender-should also be investigated.
Published: 2018

17. Work-Related Outcomes in Self-Employed Cancer Survivors: A European Multi-country Study

Author: Caroline Alleaume, Angela G. E. M. de Boer, Alain Paraponaris, Sietske J. Tamminga, Nick Van Campenhout, Elke Van Hoof, Steffen Torp, Marja-Liisa Lindbohm, Linda Sharp, Department of Health, Social & Welfare Studies [Tønsberg, Norway], University of South-Eastern Norway (USN), Aix-Marseille Sciences Economiques (AMSE), École des hautes études en sciences sociales (EHESS)-Aix Marseille Université (AMU)-École Centrale de Marseille (ECM)-Centre National de la Recherche Scientifique (CNRS), Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille] (ORS PACA), Faculty of Psychology and Education Sciences [Brussels, Belgium], Vrije Universiteit [Brussels] (VUB), Finnish Institute of Occupational Health [Helsinki, Finland], University of Tampere [Finland], Coronel Institute of Occupational Health [Amsterdam, The Netherlands] (Academic Medical Center), Amsterdam Public Health Research Institute [The Netherlands], Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institute of Health & Society [Newcastle upon Tyne, UK], Newcastle University [Newcastle], Brussels Heritage Lab, Psychology, Brain, Body and Cognition, Clinical and Lifespan Psychology, Faculty of Law and Criminology, University College of Southeast Norway (USN), ORS PACA, École des hautes études en sciences sociales (EHESS)-École Centrale de Marseille (ECM)-Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU), Vrije Universiteit Brussel (VUB), National Cancer Registry Ireland (NCRIE), KOm op tegen Kanker, Flemish Cancer League (Belgium) Nordic Cancer Union (Finland) Finnish Work Environment Fund (Finland) Finnish Cancer Organisations (Finland) National Cancer Institute (Institut National du Cancer, France) Health Research Board (Ireland) Irish Cancer Society (Ireland) Prostate Cancer UK (Ireland) Health Research Board (UK) Irish Cancer Society (UK) Prostate Cancer UK (UK) Dutch Cancer Society (Netherlands) Norwegian Cancer Society (Norway), Lhuillier, Elisabeth, Coronel Institute of Occupational Health, APH - Societal Participation & Health, APH - Quality of Care, and CCA - Cancer Treatment and Quality of Life
Subjects: Employment, Quality of life, Social security, 030506 rehabilitation, Employment/classification, Return to work, Social Welfare, Work related, 03 medical and health sciences, 0302 clinical medicine, Occupational Therapy, Cancer Survivors, Social Security/standards, Surveys and Questionnaires, Medicine, Humans, Self-employment, Financial compensation, [SHS.ECO] Humanities and Social Sciences/Economics and Finance, Cancer survivor, business.industry, Rehabilitation, 1. No poverty, [SHS.ECO]Humanities and Social Sciences/Economics and Finance, 030210 environmental & occupational health, humanities, 3. Good health, Europe, Health psychology, Cross-Sectional Studies, Survey data collection, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, 0305 other medical science, business, Demography, Cancer Survivors/statistics & numerical data
Abstract: International audience; Purpose To describe: (i) patterns of self-employment and social welfare provisions for self-employed and salaried workers in several European countries; (ii) work-related outcomes after cancer in self-employed people and to compare these with the work-related outcomes of salaried survivors within each sample; and (iii) work-related outcomes for self-employed cancer survivors across countries. Methods Data from 11 samples from seven European countries were included. All samples had cross-sectional survey data on work outcomes in self-employed and salaried cancer survivors who were working at time of diagnosis (n = 22–261 self-employed/101–1871 salaried). The samples included different cancers and assessed different outcomes at different times post-diagnosis. Results Fewer self-employed cancer survivors took time off work due to cancer compared to salaried survivors. More self-employed than salaried survivors worked post-diagnosis in almost all countries. Among those working at the time of survey, self-employed survivors had made a larger reduction in working hours compared to pre-diagnosis, but they still worked more hours per week post-diagnosis than salaried survivors. The self-employed had received less financial compensation when absent from work post-cancer, and more self-employed, than salaried, survivors reported a negative financial change due to the cancer. There were differences between self-employed and salaried survivors in physical job demands, work ability and quality-of-life but the direction and magnitude of the differences differed across countries. Conclusion Despite sample differences, self-employed survivors more often continued working during treatment and had, in general, worse financial outcomes than salaried cancer survivors. Other work-related outcomes differed in different directions across countries.
Published: 2018

18. Monitoring of asparagine depletion and anti-L-asparaginase antibodies in adult acute lymphoblastic leukemia treated in the pediatric-inspired GRAALL-2005 trial

Author: Mathilde Hunault-Berger, Xavier Thomas, Véronique Lhéritier, Norbert Ifrah, Christine Vianey-Saban, Hervé Dombret, Cécile Acquaviva-Bourdain, Thibaut Leguay, Jérôme Paillassa, Marie Audrain, Cécile Pagan, Nicolas Boissel, Françoise Huguet, Innate immunity and Immunotherapy ( CRCINA - Département INCIT - Equipe 7 ), Centre de recherche de Cancérologie et d'Immunologie / Nantes - Angers ( CRCINA ), Université d'Angers ( UA ) -Université de Nantes ( UN ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Institut de Recherche en Santé de l'Université de Nantes ( IRS-UN ) -Centre hospitalier universitaire de Nantes ( CHU Nantes ) -Université d'Angers ( UA ) -Université de Nantes ( UN ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Institut de Recherche en Santé de l'Université de Nantes ( IRS-UN ) -Centre hospitalier universitaire de Nantes ( CHU Nantes ), Service des maladies du sang [Angers], CHU Angers, Service d’hématologie Clinique [CHU Bordeaux], CHU Bordeaux [Bordeaux], Service d’Hématologie Clinique [CHU de Lyon], CHU de Lyon, Service d’hématologie Clinique [CHU Toulouse], CHU Toulouse [Toulouse], Laboratoire d'Immunologie [CHU Nantes], Centre hospitalier universitaire de Nantes ( CHU Nantes ), Coordination du Groupe GRAALL [CH Lyon-Sud], Centre Hospitalier Lyon Sud [CHU - HCL] ( CHLS ), Hospices Civils de Lyon ( HCL ) -Hospices Civils de Lyon ( HCL ), Service Maladies Héréditaires du Métabolisme et Dépistage Néonatal [CHU Lyon] ( Centre de Biologie et Pathologie Est ), Hospices Civils de Lyon ( HCL ) -Groupement Hospitalier Est, Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille] ( ORS PACA ), Service d'hématologie-oncologie adultes, Assistance publique - Hôpitaux de Paris (AP-HP)-Université Paris Diderot - Paris 7 ( UPD7 ) -Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Innate Immunity and Immunotherapy (CRCINA-ÉQUIPE 7), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Service Maladies Héréditaires du Métabolisme et Dépistage Néonatal [CHU Lyon] (Centre de Biologie et Pathologie Est), Hospices Civils de Lyon (HCL)-Groupement Hospitalier Est, Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille] (ORS PACA), Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Service Hématologie - IUCT-Oncopole [CHU Toulouse], Pôle Biologie [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle IUCT [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], and Bernardo, Elizabeth
Subjects: Male, [SDV.CAN]Life Sciences [q-bio]/Cancer, Pharmacology, lcsh:RC254-282, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, L asparaginase, 03 medical and health sciences, 0302 clinical medicine, [SDV.CAN] Life Sciences [q-bio]/Cancer, Isoantibodies, Correspondence, Medicine, Asparaginase, Humans, Asparagine, Child, ComputingMilieux_MISCELLANEOUS, biology, business.industry, Hematology, Precursor Cell Lymphoblastic Leukemia-Lymphoma, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, 3. Good health, Clinical trial, Oncology, Clinical Trials, Phase III as Topic, 030220 oncology & carcinogenesis, Adult Acute Lymphoblastic Leukemia, biology.protein, Female, Antibody, business, 030215 immunology
Abstract: International audience; no abstract
Published: 2018

19. Médecins généralistes et vaccination des enfants présentant une infection fébrile non compliquée

Author: Le Marechal, M., Fressard, L., Raude, Jocelyn, Verger, P., Pulcini, C., Maladies chroniques, santé perçue, et processus d'adaptation (APEMAC), Université de Lorraine (UL), Observatoire Régional de la Santé de Provence-Alpes-Cote d'Azur, ORS PACA, Vecteurs - Infections tropicales et méditerranéennes (VITROME), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées (IRBA), EHESP Rennes, Sorbonne Paris Cité, Rennes, France AND Inserm, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille] (ORS PACA), École des Hautes Études en Santé Publique [EHESP] (EHESP), Emergence des Pathologies Virales (EPV), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM), F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), Service des Maladies Infectieuses et Tropicales [CHRU Nancy], and Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)
Subjects: Vaccination Mots clés : Fièvre, [SHS.SOCIO]Humanities and Social Sciences/Sociology, Fever, education, Vaccination, General practitioner, Fièvre, Immunisation, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Médecin généraliste, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Immunization, Children, ComputingMilieux_MISCELLANEOUS
Abstract: International audience; Purpose: To assess the self-reported vaccination behavior of general practitioners (GPs) when asked whether they would recommend the vaccination of a child presenting with a febrile uncomplicated common cold. Methods: We performed a cross-sectional survey in 2014 on a national sample of GPs. GPs were randomly assigned to one of eight clinical vignettes, all describing a child presenting with an uncomplicated febrile common cold, but differing by age (4 or 11 months), temperature (38 °C or 39 °C), and the mother's emotional state (calm or worried). GPs were asked whether they would recommend immediate vaccination of the child with a hexavalent vaccine (diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type b, and hepatitis B), or postpone it. We investigated the relation between the GPs’ recommendation to vaccinate, the clinical vignette's variables, and the GPs’ perceptions, attitudes, and practices toward vaccination in a multivariate model. Results: Among the 1582 participating GPs, 6% recommended immediate vaccination. This behavior was more frequent with a temperature of 38 °C rather than 39 °C (10% vs. 3%, P < 0.001). GPs who felt comfortable giving explanations about vaccine safety were more likely to recommend immediate vaccination of the febrile child (P = 0.045), but none of the other GPs’ characteristics were associated with their vaccination behavior. Conclusions: Almost all GPs postponed the hexavalent vaccination of the febrile child presenting with an uncomplicated viral disease; fever being the major factor affecting their decision. More research is needed on vaccination responses in sick children, as well as clearer guidelines.
Published: 2018

20. Efficacy and safety of boceprevir-based triple therapy in HCV cirrhotic patients awaiting liver transplantation (ANRS HC29 BOCEPRETRANSPLANT)

Author: Amir Guidoum, Laurent Alric, Vincent Leroy, Si-Nafa Si-Ahmed, Didier Samuel, Jean-Charles Duclos-Vallée, Jean-Didier Grangé, Sébastien Dharancy, Lawrence Serfaty, Célia Wellems, Christophe Hézode, François Durand, Anne-Marie Taburet, François Bailly, Christelle Paul, Maria Patrizia Carrieri, Pierre Pradat, Cécile Bouix, Elina Teicher, Sophie Metivier, Antoine Vilotitch, Christophe Duvoux, Georges-Philippe Pageaux, Anne-Marie Roque-Afonso, Bruno Roche, Filomena Conti, Ventzislava Petrov-Sanchez, Rodolphe Anty, Hélène Fontaine, Frédérik Beaulieux, Michelle Sizorn, Louis d’Alteroche, Marianne Maynard, Valérie Canva, Danielle Botta-Fridlund, Pascal Lebray, Département d'hépatologie [CHU Cochin], Institut Pasteur [Paris]-CHU Cochin [AP-HP]-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université Paris Descartes - Paris 5 ( UPD5 ), Service d'Hépatologie [Hôpital de la Croix-Rousse - HCL], Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon ( HCL ) -Hospices Civils de Lyon ( HCL ), Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale ( SESSTIM - U912 INSERM - Aix Marseille Univ - IRD ), Institut de Recherche pour le Développement ( IRD ) -Aix Marseille Université ( AMU ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), ORS PACA, Hôpital de la Conception [CHU - APHM] ( LA CONCEPTION ), Département d'hépato-gastro-entérologie [Hôpital Trousseau : CHRU Tours], CHU Trousseau [APHP]-Centre Hospitalier Régional Universitaire de Tours ( CHRU TOURS ), Service d'hépatologie [Saint-Antoine], Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Saint-Antoine [APHP], Fédération Médico-Chirurgicale des Maladies de l'Appareil Digestif, Centre Hospitalier Régional Universitaire [Montpellier] ( CHRU Montpellier ) -CHU Saint-Eloi, Département d'hépato-gastroentérologie, Université Joseph Fourier - Grenoble 1 ( UJF ) -CHU Grenoble, Service de Gastro-entérologie - Hépatologie [Purpan], CHU Toulouse [Toulouse]-Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse], Centre Hospitalier Universitaire de Nice ( CHU Nice ), Service d’Hépatologie [Hôpital Beaujon], Hôpital Beaujon, Hôpital Claude Huriez, Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] ( CHRU Lille ), Service d'Hépato-Gastroentérologie [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Pitié-Salpêtrière [APHP], Hôpital Purpan [Toulouse], Service d'hépato-gastro-entérologie [APHP Henri Mondor], Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), ANRS, France REcherche Nord & sud Sida-hiv Hépatites (FRENSH), Unit for Basic and Clinical research on Viral Hepatitis, Centre hépato-biliaire ( CHB ), Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Physiopathologie et traitement des maladies du foie, Université Paris-Sud - Paris 11 ( UP11 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -AP-HP Hôpital Paul Brousse, This work was funded and sponsored by ANRS (France REcherche Nord & sud Sida-HIV Hépatites [FRENSH]), Paris.Dr Fontaine reports personal fees from Gilead, Janssen, BMS, MSD, AbbVie, outside the submitted work.Dr Leroy reports advisory role for BMS, Gilead, AbbVie, and Janssen and personal fees from BMS, Gilead, AbbVie, and Janssen.Dr Alric reports personal fees from MSD, Janssen, Gilead, AbbVie, BMS, research grants from MSD, Janssen, Gilead, AbbVie, BMS, and non-financial support from MSD, Janssen, Gilead, AbbVie, BMS., The authors thank Audrey Kremer-Cochet, Laure Roguet, and Dr Alpha Diallo for their continued deep involvement in the study. They also thank members of the independent committee: Prof Eric Belissant (methodologist), Dr Michel Biour (pharmacologist), Dr Marc Bourlière (hepatologist), Dr Rodolphe Garraffo (pharmacologist), Prof Dominique Larrey (pharmacologist), Prof Philippe Mathurin (hepatologist), Prof Christophe Moréno (hepatologist). They also thank Merck Schering-Plough for supplying the boceprevir. Finally, the authors thank the patients and their families., Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris Descartes - Paris 5 (UPD5), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U912 INSERM - Aix Marseille Univ - IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Saint Eloi (CHRU Montpellier), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), CHU Grenoble-Université Grenoble Alpes (UGA), Pôle Maladies de l'appareil digestif [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre Hospitalier Universitaire de Nice (CHU Nice), Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Claude Huriez [Lille], CHU Lille, CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), ANRS France Recherche Nord & sud Sida-hiv hépatites, Centre hépato-biliaire (CHB), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Département d'hépathologie - Hôpital Cochin [Paris], Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -CHU Cochin [AP-HP], Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale ( SESSTIM ), Institut de Recherche pour le Développement ( IRD ) -Aix Marseille Université ( AMU ) -ORS PACA-Institut National de la Santé et de la Recherche Médicale ( INSERM ), CHU Nice, Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Cochin [AP-HP], Institut de Recherche pour le Développement (IRD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU), Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS)-CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Université Pierre et Marie Curie - Paris 6 (UPMC), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-CHU Saint-Eloi, Université Grenoble Alpes (UGA)-CHU Grenoble, Service d'Hépato-Gastro-Entérologie [CHU Pitié-Salpêtrière], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Pharmacochimie et Biologie pour le Développement (PHARMA-DEV), Institut de Recherche pour le Développement (IRD)-Institut de Chimie de Toulouse (ICT-FR 2599), Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC), Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Paul Brousse-Université Paris-Sud - Paris 11 (UP11), Herrada, Anthony, CHU Trousseau [APHP], Service d'hépatologie [CHU Saint-Antoine], Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), and Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-CHU Trousseau [APHP]
Subjects: Liver Cirrhosis, Male, medicine.medical_treatment, Liver transplantation, Gastroenterology, chemistry.chemical_compound, Liver disease, 0302 clinical medicine, 030212 general & internal medicine, Liver Neoplasms, Hepatitis C, Middle Aged, 3. Good health, Treatment Outcome, Hepatocellular carcinoma, Drug Therapy, Combination, Female, 030211 gastroenterology & hepatology, [ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, France, Adult, medicine.medical_specialty, Carcinoma, Hepatocellular, Adolescent, Proline, Antiviral Agents, 03 medical and health sciences, Pharmacotherapy, Internal medicine, Boceprevir, Ribavirin, medicine, Humans, Adverse effect, Aged, Retrospective Studies, Hepatology, business.industry, Interferon-alpha, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, Hepatitis C, Chronic, medicine.disease, [SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, Liver Transplantation, Surgery, chemistry, Quality of Life, business
Abstract: International audience; BACKGROUND AND AIMS:In this French multicentre, open-label study, we analyzed the efficacy, safety and patient-reported outcomes of a boceprevir-based triple therapy in HCV genotype 1 cirrhotic patients awaiting liver transplantation (LT).METHODS:Patients received PEG-IFN/ribavirin (RBV) for 48 weeks (W) and boceprevir from W4 to W48 or until LT.RESULTS:Fifty-one patients (80% males, median age: 56 years) were included. Fifty-seven percent had hepatocellular carcinoma and 43% end-stage liver disease. At enrolment, the median MELD score was 9 (range: 6-18); the Child-Pugh score was A in 65%, B in 35% and C in 2%. Therapy was discontinued because of severe adverse events (SAEs) in 39% of cases and virological inefficacy in 24%. 16% of patients had undetectable HCV RNA 24 weeks after the end of treatment (SVR24). LT was performed in 18 patients (35%). HCV RNA was undetectable in 16.6% at LT. Seven patients (14%) died and three deaths were attributed to treatment. SAEs (n=129) were observed in 84% of patients. Twenty-four percent of patients developed severe infections. Albumin
Published: 2017

21. Effectiveness of a French mass‐media campaign in raising knowledge of both long‐term alcohol‐related harms and low‐risk drinking guidelines, and in lowering alcohol consumption

Author: Guillemette Quatremère, Romain Guignard, Chloé Cogordan, Raphaël Andler, Karine Gallopel‐Morvan, Viêt Nguyen‐Thanh, Santé publique France Guyane, Santé publique France - French National Public Health Agency [Saint-Maurice, France], ORS PACA, Centre de Recherches sur l'Action Politique en Europe (ARENES), Université de Rennes (UR)-Institut d'Études Politiques [IEP] - Rennes-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Centre National de la Recherche Scientifique (CNRS), Recherche sur les services et le management en santé (RSMS), Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), École des Hautes Études en Santé Publique [EHESP] (EHESP), Institut du Management (IDM), and This study was funded by Santé publique France
Subjects: knowledge, Psychiatry and Mental health, evaluation, prevention, low-risk drinking guidelines, long-term alcohol-related harms, effectiveness, Medicine (miscellaneous), alcohol-related risks, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, media campaign, Alcohol, social marketing
Abstract: International audience; Aims: To evaluate the effectiveness of a French mass-media campaign in raising knowledge of both long-term alcohol-related harms (LTH) and low-risk drinking guidelines (LRDG), as well as in lowering alcohol consumption.Design: An 8-month longitudinal survey from February to October 2019, with three waves of on-line data collection (T0 before the campaign, T1 just after it ended and T2 6 months after it ended).Setting: France.Participants: A total of 2538 adult drinkers (aged 18-75 years).Measurements: The main outcomes' variables were LTH knowledge (cancer, hypertension, brain haemorrhage), LRDG knowledge (two guidelines: 'maximum of two drinks a day' and 'minimum of 2 days without alcohol per week'), intention to reduce alcohol consumption and self-declared consumption with respect to the French LRDG. At T1, exposure to the campaign was measured using self-reported campaign recall.Findings: In T1, we observed significant positive interactions between exposure group based on campaign recall and survey waves on knowledge of (i) the 'maximum two drinks a day' guideline [adjusted odds ratio (aOR) = 1.32, 95% confidence interval (CI) = 1.08-1.62, P = 0.008], (ii) brain haemorrhage (aOR = 1.80, 95% CI = 1.44-2.25, P < 0.001) and (iii) hypertension (aOR = 1.41, 95% CI = 1.09-1.81, P = 0.008) risks. Campaign exposure was also associated with a significant decrease in at-risk drinking in women (aOR = 0.67, 95% CI = 0.50-0.88, P = 0.004). No significant interaction was observed at T1 for the knowledge of the 'minimum of 2 days without alcohol a week' guideline, or of cancer risk. At T2, no significant interaction was observed for the main outcomes' variables.Conclusions: There appears to be an association between exposure to a 2019 French mass-media campaign to raise knowledge of long-term alcohol-related harms and low-risk drinking guidelines and reduce alcohol consumption and (i) improved knowledge of the 'maximum two drinks per day guideline', (ii) knowledge of the risks of hypertension and brain haemorrhage and (iii) a reduction in the proportion of people exceeding low-risk drinking guidelines (in the general population only). These associations were only observed over the short term and, in some cases, only for certain segments of the population.
Published: 2022

22. Clinical and Molecular Findings in 39 Patients with KBG Syndrome Caused by Deletion or Mutation of ANKRD11

Author: Aurélia Jacquette, Alice Goldenberg, Thierry Frebourg, Julien Thevenon, David Geneviève, Anne-Marie Guerrot, Andrée Delahaye-Duriez, Yline Capri, Bruno Leheup, François Lecoquierre, Florence Riccardi, Tiffany Busa, Laurent Villard, Pierre Cacciagli, Vincent Gatinois, Julien Mancini, Chantal Missirian, Lionel Van Maldergem, Massimiliano Rossi, Laurence Perrin, Catherine Vincent-Delorme, Pascale Saugier-Veber, Philippe Khau Van Kien, Gwenaël Nadeau, Annick Toutain, Alain Verloes, Sandrine Marlin, Rolph Pfundt, Elise Schaefer, Arthur Sorlin, Vincent Michaud, Christel Thauvin-Robinet, Philippe Parent, Cyril Mignot, Charles Coutton, Nicole Philip, Véronique Satre, Aude Tessier, Service de génétique [Rouen], CHU Rouen-Université de Rouen Normandie ( UNIROUEN ), Normandie Université ( NU ) -Normandie Université ( NU ), Génétique Médicale et Génomique Fonctionnelle ( GMGF ), Aix Marseille Université ( AMU ) -Assistance Publique - Hôpitaux de Marseille ( APHM ) - Hôpital de la Timone [CHU - APHM] ( TIMONE ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Department of Human Genetics, Département de génétique, Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Robert Debré-Université Paris Diderot - Paris 7 ( UPD7 ), Institut d'oncologie/développement Albert Bonniot de Grenoble ( INSERM U823 ), Université Joseph Fourier - Grenoble 1 ( UJF ) -CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Hôpital Jean Verdier, Génétique du cancer et des maladies neuropsychiatriques ( GMFC ), Université de Rouen Normandie ( UNIROUEN ), Normandie Université ( NU ) -Normandie Université ( NU ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), CHU Rouen, Cellules souches mésenchymateuses, environnement articulaire et immunothérapies de la polyarthrite rhumatoide, Université Montpellier 1 ( UM1 ) -IFR3-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Service de Génétique Cytogénétique et Embryologie [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Pitié-Salpêtrière [APHP], Centre Hospitalier Régional Universitaire de Nîmes ( CHRU Nîmes ), Service de Génétique Médicale [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy ( CHRU Nancy ), CHU Trousseau [APHP], Physiopathologie et neuroprotection des atteintes du cerveau en développement, Université Paris Diderot - Paris 7 ( UPD7 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), École Supérieure des Géomètres et Topographes ( ESGT CNAM ), Conservatoire National des Arts et Métiers [CNAM] ( CNAM ), Laboratoire de Géodésie et de Géomatique ( L2G ESGT CNAM ), Conservatoire National des Arts et Métiers [CNAM] ( CNAM ) -Conservatoire National des Arts et Métiers [CNAM] ( CNAM ) -Conservatoire National des Arts et Métiers [CNAM] ( CNAM ), Service de Cytogénétique, Centre hospitalier de Valence, Centre de Référence des Déficiences Intellectuelles de Causes Rares, Centre Interdisciplinaire de Nanoscience de Marseille ( CINaM ), Aix Marseille Université ( AMU ) -Centre National de la Recherche Scientifique ( CNRS ), Centre de recherche en neurosciences de Lyon ( CRNL ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] ( UJM ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Service de génétique [Tours], Hôpital Bretonneau-CHRU Tours, Service de Génétique, Hôpital de Hautepierre [Strasbourg], Centre de génétique - Centre de référence des maladies rares, anomalies du développement et syndromes malformatifs (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Laboratoire Chrono-environnement ( LCE ), Université Bourgogne Franche-Comté ( UBFC ) -Centre National de la Recherche Scientifique ( CNRS ) -Université de Franche-Comté ( UFC ), AGeing and IMagery ( AGIM ), Université Pierre Mendès France - Grenoble 2 ( UPMF ) -Université Joseph Fourier - Grenoble 1 ( UJF ) -École pratique des hautes études ( EPHE ) -Centre National de la Recherche Scientifique ( CNRS ), Service de génétique [Robert Debré], Assistance publique - Hôpitaux de Paris (AP-HP), Centre de Maladies Rares, Anomalies du Développement Nord de France-CH Arras - CHRU Lille, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale ( SESSTIM ), Institut de Recherche pour le Développement ( IRD ) -Aix Marseille Université ( AMU ) -ORS PACA-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Institut Paoli Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Biostatistique et technologies de l'information et de la communication (BioSTIC) - [Hôpital de la Timone - APHM] ( BiosTIC ), Assistance Publique - Hôpitaux de Marseille ( APHM ) -Aix Marseille Université ( AMU ) -Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale ( SESSTIM ), Institut de Recherche pour le Développement ( IRD ) -Aix Marseille Université ( AMU ) -ORS PACA-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Institut de Recherche pour le Développement ( IRD ) -Aix Marseille Université ( AMU ) -ORS PACA-Institut National de la Santé et de la Recherche Médicale ( INSERM ) - Hôpital de la Timone [CHU - APHM] ( TIMONE ), Assistance Publique - Hôpitaux de Marseille ( APHM ) - Hôpital de la Timone [CHU - APHM] ( TIMONE ), Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Génétique Médicale et Génomique Fonctionnelle (GMGF), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Radboud University Medical Center [Nijmegen], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Robert Debré-Université Paris Diderot - Paris 7 (UPD7), Institut d'oncologie/développement Albert Bonniot de Grenoble (INSERM U823), Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Jean Verdier [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Génétique du cancer et des maladies neuropsychiatriques (GMFC), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU de Bordeaux Pellegrin [Bordeaux], Centre Interdisciplinaire de Nanoscience de Marseille (CINaM), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Centre de recherche en neurosciences de Lyon (CRNL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), AGeing and IMagery (AGIM), Centre National de la Recherche Scientifique (CNRS)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Joseph Fourier - Grenoble 1 (UJF)-Université Pierre Mendès France - Grenoble 2 (UPMF), Département de génétique [Robert Debré], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP Hôpital universitaire Robert-Debré [Paris], Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U912 INSERM - Aix Marseille Univ - IRD), Institut de Recherche pour le Développement (IRD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU), Institut Paoli-Calmettes, Biostatistique et technologies de l'information et de la communication (BioSTIC) - [Hôpital de la Timone - APHM] (BiosTIC ), Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center (CRNL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université Pierre Mendès France - Grenoble 2 (UPMF)-Université Joseph Fourier - Grenoble 1 (UJF)-École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Gall, Valérie, Université Pierre Mendès France - Grenoble 2 (UPMF)-Université Joseph Fourier - Grenoble 1 (UJF)-École pratique des hautes études (EPHE), Institut National de la Santé et de la Recherche Médicale (INSERM)-EFS-CHU Grenoble-Université Joseph Fourier - Grenoble 1 (UJF), Hôpital Bretonneau-Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), and Hôpital de la Timone [CHU - APHM] (TIMONE)-Assistance Publique - Hôpitaux de Marseille (APHM)
Subjects: Male, 0301 basic medicine, 030105 genetics & heredity, medicine.disease_cause, Bioinformatics, Intellectual disability, Child, Genetics (clinical), Genetics, Comparative Genomic Hybridization, Mutation, Middle Aged, KBG syndrome, Phenotype, [ SDV.BBM.GTP ] Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN], Child, Preschool, [SDV.BBM.GTP] Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN], Female, Chromosome Deletion, medicine.symptom, Haploinsufficiency, Adult, Adolescent, Biology, Malignancy, Short stature, ANKRD11, Young Adult, 03 medical and health sciences, Intellectual Disability, [SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN], medicine, Humans, Precocious puberty, Abnormalities, Multiple, long-term prognosis, Alleles, Genetic Association Studies, Aged, Retrospective Studies, Bone Diseases, Developmental, Neurodevelopmental disorders Donders Center for Medical Neuroscience [Radboudumc 7], Tooth Abnormalities, 16q24.3 deletion, Point mutation, Facies, Infant, medicine.disease, haploinsufficiency, Repressor Proteins, Amino Acid Substitution, Autism, Chromosomes, Human, Pair 16
Abstract: Item does not contain fulltext KBG syndrome, due to ANKRD11 alteration is characterized by developmental delay, short stature, dysmorphic facial features, and skeletal anomalies. We report a clinical and molecular study of 39 patients affected by KBG syndrome. Among them, 19 were diagnosed after the detection of a 16q24.3 deletion encompassing the ANKRD11 gene by array CGH. In the 20 remaining patients, the clinical suspicion was confirmed by the identification of an ANKRD11 mutation by direct sequencing. We present arguments to modulate the previously reported diagnostic criteria. Macrodontia should no longer be considered a mandatory feature. KBG syndrome is compatible with autonomous life in adulthood. Autism is less frequent than previously reported. We also describe new clinical findings with a potential impact on the follow-up of patients, such as precocious puberty and a case of malignancy. Most deletions remove the 5'end or the entire coding region but never extend toward 16q telomere suggesting that distal 16q deletion could be lethal. Although ANKRD11 appears to be a major gene associated with intellectual disability, KBG syndrome remains under-diagnosed. NGS-based approaches for sequencing will improve the detection of point mutations in this gene. Broad knowledge of the clinical phenotype is essential for a correct interpretation of the molecular results. (c) 2016 Wiley Periodicals, Inc.
Published: 2016

23. Sexual risk behaviour among people living with HIV according to the biomedical risk of transmission: results from the ANRS-VESPA2 survey

Author: Rosemary Dray-Spira, Baptiste Demoulin, Marie Préau, Fabienne Marcellin, Marie Suzan-Monti, Nicolas Lorente, Bruno Spire, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U912 INSERM - Aix Marseille Univ - IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de Recherche pour le Développement (IRD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), ORS PACA, Groupe de Recherche en Psychologie Sociale (GRePS), Université Lumière - Lyon 2 (UL2), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse, HAL-UPMC, Gestionnaire, Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille] (ORS PACA), Centro de Fisica de Materiales (CFM), Universidad del Pais Vasco / Euskal Herriko Unibertsitatea [Espagne] (UPV/EHU)-Consejo Superior de Investigaciones Científicas [Madrid] (CSIC), Donostia International Physics Center - DIPC (SPAIN), Donostia International Physics Center (DIPC), and University of the Basque Country/Euskal Herriko Unibertsitatea (UPV/EHU)-University of the Basque Country/Euskal Herriko Unibertsitatea (UPV/EHU)
Subjects: Adult, Male, 0301 basic medicine, Sexual partner, medicine.medical_specialty, biomedical risk of HIV transmission, Anti-HIV Agents, Cross-sectional study, Sexual Behavior, [SDV]Life Sciences [q-bio], sexual risk behaviour, Sexually Transmitted Diseases, HIV Infections, Men who have sex with men, law.invention, 03 medical and health sciences, Risk-Taking, 0302 clinical medicine, 5. Gender equality, Condom, law, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, medicine, Humans, 030212 general & internal medicine, Retrospective Studies, Gynecology, Transmission (medicine), business.industry, Public Health, Environmental and Occupational Health, HIV, Retrospective cohort study, Middle Aged, 030112 virology, Cross-Sectional Studies, Infectious Diseases, Serodiscordant, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, [SDV.IMM]Life Sciences [q-bio]/Immunology, Female, successful ART, business, Viral load, Research Article, Demography
Abstract: International audience; Introduction: People living with HIV (PLHIV) on antiretroviral therapy (ART), with sustained undetectable viral load (sUVL) and no history of sexually transmitted infections for at least six months, are considered to have a low risk of HIV transmission (LRT). We aimed to characterize, in a representative sample of French PLHIV, the sexual behaviour of LRT PLHIV compared with non-LRT PLHIV. Methods: The cross-sectional ANRS-VESPA2 survey was conducted on adult PLHIV attending French hospitals in 2011. The LRT PLHIV group included participants with sUVL and no sexually transmitted infection for at least 12 months. Socio-behavioural and medical data were collected. Chi-square tests helped compare sexual risk indicators between LRT and non-LRT PLHIV. The survey's retrospective nature allowed us to perform complementary category-based analyses of LRT PLHIV according to whether they had sUVL for at least 18, 24 or 36 months in three socio-epidemiological groups: men who have sex with men (MSM), other men and women. Results: Analysis included 2638 PLHIV diagnosed !12 months with available viral load data. The proportion of LRT PLHIV varied from 58% (]12 months sUVL) to 38% (]36 months sUVL). Irrespective of sUVL duration, we found the following: 1) LRT men (MSM and other men) were more likely to report having no sexual partner than their non-LRT counterparts. Among men having sexual partners in the previous 12 months, no significant difference was seen between LRT and non-LRT men in the number of sexual partners. LRT women were less likely to report having more than one sexual partner than non-LRT women; 2) LRT MSM were more likely to report being in sexually inactive couples than their non-LRT counterparts; 3) among sexually active participants, no difference was observed between LRT and non-LRT PLHIV concerning condom use with their serodiscordant steady partner or with their most recent casual sexual partners. Conclusions: LRT PLHIV with sUVL ]12 months did not report more sexual risk behaviours than their non-LRT counterparts. Because the same result was obtained for those having a sUVL ]36 months, the hypothesis of increased sexual risk behaviour over time in PLHIV meeting non-transmission biomedical criteria is not supported.
Published: 2016

24. Factors associated with satisfaction with community-based non-medicalized counseling and testing using HIV rapid tests among MSM in France

Author: Préau, Marie, Lorente, Nicolas, Sagaon Teyssier, Luis, Champenois, Karen, Le Gall, Jean-Marie, Xavier, Mabire, Spire, Bruno, Mora, Marion, Yazdanpanah, Yazdan, Suzan-Monti, Marie, Group, Anrs-Drag, Group, Anrs-Comtest, Greps, Laboratoire, Groupe de Recherche en Psychologie Sociale (GRePS), Université Lumière - Lyon 2 (UL2), Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U912 INSERM - Aix Marseille Univ - IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille] (ORS PACA), Evaluation des technologies de santé et des pratiques médicales - ULR 2694 (METRICS), Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Methodology, Innovation, Research, Evaluation (MIRE), AIDES, Service des maladies infectieuses et tropicales, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de Recherche pour le Développement (IRD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU), Inflammation: mécanismes et régulation et interactions avec la nutrition et les candidoses, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille, Droit et Santé, Epidémiologie et Sciences Sociales Appliquées à l'Innovation Médicale, Université de la Méditerranée - Aix-Marseille 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Services de Maladies Infectieuses et Tropicales [CHU Bichat], AP-HP - Hôpital Bichat - Claude Bernard [Paris], Observatoire Régional de la Santé PACA, ORS PACA, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Université de Lille, Université Paris Diderot - Paris 7 (UPD7)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC), and Université de Lille, Droit et Santé-Institut National de la Santé et de la Recherche Médicale (INSERM)
Subjects: Gerontology, Counseling, Male, Safe Sex, Health Knowledge, Attitudes, Practice, Health (social science), Human immunodeficiency virus (HIV), [SHS.PSY]Humanities and Social Sciences/Psychology, Human sexuality, HIV Infections, medicine.disease_cause, community-based research, Men who have sex with men, law.invention, Condoms, 0302 clinical medicine, prevention, law, PARTICIPATION POPULAIRE, Surveys and Questionnaires, 030212 general & internal medicine, Community Health Services, ComputingMilieux_MISCELLANEOUS, Community based, SIDA, SCIENCE PARTICIPATIVE, Patient Satisfaction, COMPORTEMENT SEXUEL, France, 0305 other medical science, Psychosocial, Clinical psychology, Adult, Social Psychology, Sexual Behavior, [SHS.PSY] Humanities and Social Sciences/Psychology, 03 medical and health sciences, Patient satisfaction, Condom, medicine, Humans, MSM, Homosexuality, Male, 030505 public health, business.industry, Public Health, Environmental and Occupational Health, ANTHROPOLOGIE DE LA SANTE, Meeting place, PREVENTION SANITAIRE, Rapid testing, ENQUETE, business, Risk Reduction Behavior
Abstract: International audience; The aims of the study were to determine the level of satisfaction of men who have sex with men (MSM) participating in two community-based non-medicalized counseling and testing programs (ANRS-DRAG and ANRS-COM'TEST) offering HIV rapid tests (hereafter CBOffer), and to identify factors associated with satisfaction. Between 2009 and 2011, 436 participants voluntarily benefited from a CBOffer in the two programs. They completed self-administered questionnaires before and after testing. Psychosocial scores were constructed using principal component analyses to reflect the following dimensions: post-test satisfaction, avoidance of at-risk situations as a HIV risk-reduction strategy, and attitudes towards condom use. Logarithmic regression of the post-test satisfaction score was performed on these scores and on other selected explanatory variables, including the variable "self-identification as homosexual or bisexual". Post-test satisfaction ranged between 90-99 and below 90 for 50% and 25% of the participants, respectively. Post-test satisfaction with the CBOffer was independently associated with self-defined sexuality, meeting place for sexual partners, participants' attitudes about being HIV-positive, and condom use. The very high level of satisfaction was associated with both personal and socio-behavioral factors. Vulnerable MSM could be targeted better and, accordingly, could use this offer more frequently as a combined prevention tool.
Published: 2016

25. Prevalence of and factors associated with depression among people living with HIV in France

Author: Jean-michel Molina, Tristan Ferry, Laure Tron, Pierre Delobel, Jean-Daniel Lelievre, Rosemary Dray-Spira, Patrizia Carrieri, Eric DENES, Victoire De Lastours, Julie BOTTERO, Bruno MARCHOU, Nicolas Lorente, Sophie Matheron, Cedric Arvieux, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U912 INSERM - Aix Marseille Univ - IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille] (ORS PACA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Institut de Recherche pour le Développement (IRD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU), Observatoire Régional de la Santé PACA, ORS PACA, and HAL-UPMC, Gestionnaire
Subjects: Male, 0301 basic medicine, [SDV.MHEP.PSM] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, HIV Infections, Men who have sex with men, 0302 clinical medicine, 5. Gender equality, Risk Factors, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Surveys and Questionnaires, Prevalence, Medicine, Pharmacology (medical), 030212 general & internal medicine, 10. No inequality, Sida, Major depressive episode, Depression (differential diagnoses), education.field_of_study, biology, Health Policy, Middle Aged, 3. Good health, Infectious Diseases, symbols, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Female, France, medicine.symptom, Adult, medicine.medical_specialty, Sexual Behavior, Population, Young Adult, 03 medical and health sciences, symbols.namesake, Humans, Poisson regression, Psychiatry, education, Socioeconomic status, Depressive Disorder, Marital Status, business.industry, biology.organism_classification, 030112 virology, Confidence interval, Logistic Models, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, Demography
Abstract: Agence Nationale de Recherche sur le Sida et les Hépatites Virales (ANRS)-VIH: Enquête sur les personnes atteintes (Vespa2) Study Group; International audience; Objectives: Depression is common among people living with HIV (PLWHIV) and is associated with poorer therapeutic outcomes and risky behaviours. We sought to estimate the prevalence of major depressive episode (MDE) across PLWHIV groups, to compare this with its prevalence in the general population and to assess factors associated with it.Methods: We used data from the Agence Nationale de Recherche sur le Sida et les Hépatites Virales (ANRS)-Vespa2 study, a national study on a representative sample of PLWHIV conducted in France in 2011. The short form of the depression module of the World Health Organization's Composite International Diagnostic Instrument (CIDI-SF) was used to characterize the occurrence of an MDE during the previous year. MDE prevalence was assessed among the various groups of PLWHIV and compared with that in the general population, accounting for the sociodemographic characteristics of the two populations, using multivariate Poisson regression models. The same method was used to assess associated factors.Results: MDE prevalence was 28.1% among PLWHIV, ranging from 10.9 to 55.7% across groups. Compared with the general population by sex, regardless of sexual orientation and origin, MDE prevalence was 5.1-fold higher in HIV-infected men who have sex with men [95% confidence interval (CI) 3.9–6.6], 3.1-fold higher in non-sub-Saharan African (SSA) heterosexual men (95% CI 2.2–4.4), 1.6-fold higher in SSA migrant men (95% CI 0.9–2.6), 2.6-fold higher in non-SSA heterosexual women (95% CI 2.1–3.3), and 1.9-fold higher in SSA migrant women (95% CI 1.5–2.5). In the HIV-infected population, MDE was positively related to unemployment, material deprivation, disclosure, experience of discrimination, and untreated hepatitis C, and negatively related to age.Conclusions: The prevalence of depression varied across the different groups of PLWHIV, with levels much higher than in the general population. Moreover, there was a strong association with socioeconomic status and HIV experience.
Published: 2016

26. Achieving universal health coverage in France : policy reforms and the challenge of inequalities

Author: Patrick Castel, Olivier Nay, Sophie Béjean, Bruno Ventelou, Daniel Benamouzig, Henri Bergeron, Centre européen de sociologie et de science politique (CESSP), Université Paris 1 Panthéon-Sorbonne (UP1)-École des hautes études en sciences sociales (EHESS)-Centre National de la Recherche Scientifique (CNRS), Equipe d'Economie de la Santé, Laboratoire d'Economie et de Gestion (LEG), Université de Bourgogne (UB)-Centre National de la Recherche Scientifique (CNRS)-Université de Bourgogne (UB)-Centre National de la Recherche Scientifique (CNRS), Centre de sociologie des organisations (Sciences Po, CNRS) (CSO), Sciences Po (Sciences Po)-Centre National de la Recherche Scientifique (CNRS), GRAPHOS - IFROSS Recherche, Université Jean Moulin - Lyon 3 (UJML), Université de Lyon-Université de Lyon, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U912 INSERM - Aix Marseille Univ - IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), ORS PACA, Groupement de Recherche en Économie Quantitative d'Aix-Marseille (GREQAM), École des hautes études en sciences sociales (EHESS)-Aix Marseille Université (AMU)-École Centrale de Marseille (ECM)-Centre National de la Recherche Scientifique (CNRS), Centre de sociologie des organisations (CSO), Institut de Recherche pour le Développement (IRD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU), École Centrale de Marseille (ECM)-École des hautes études en sciences sociales (EHESS)-Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU), Centre européen de sociologie et de science politique ( CESSP ), Université Panthéon-Sorbonne ( UP1 ) -École des hautes études en sciences sociales ( EHESS ) -Centre National de la Recherche Scientifique ( CNRS ), Laboratoire d'Economie et de Gestion ( LEG ), Université de Bourgogne ( UB ) -Centre National de la Recherche Scientifique ( CNRS ) -Université de Bourgogne ( UB ) -Centre National de la Recherche Scientifique ( CNRS ), Centre de sociologie des organisations ( CSO ), Sciences Po-Centre National de la Recherche Scientifique ( CNRS ), Université Jean Moulin - Lyon III, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale ( SESSTIM ), Institut de Recherche pour le Développement ( IRD ) -Aix Marseille Université ( AMU ) -ORS PACA-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Groupement de Recherche en Économie Quantitative d'Aix-Marseille ( GREQAM ), and Ecole Centrale de Marseille ( ECM ) -Centre National de la Recherche Scientifique ( CNRS ) -Aix Marseille Université ( AMU ) -École des hautes études en sciences sociales ( EHESS )
Subjects: Budgets, medicine.medical_specialty, French model, 030501 epidemiology, Public administration, Economic Justice, Social Security, Social insurance, 03 medical and health sciences, 0302 clinical medicine, Health Economics, Universal Health Insurance, Political science, Health care, medicine, Humans, Health Finance, 030212 general & internal medicine, Social determinants of health, Healthcare Disparities, Health Policies, Health policy, Health inequalities, Social Inequalities in Health, Health economics, business.industry, Health Policy, Public health, 1. No poverty, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, General Medicine, 16. Peace & justice, [SHS.SCIPO]Humanities and Social Sciences/Political science, 3. Good health, Health Care, Health Reforms, Health Care Reform, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Health care reform, France, Public Health, 0305 other medical science, business, [ SHS.SCIPO ] Humanities and Social Sciences/Political science
Abstract: International audience; Since 1945, the provision of health care in France has been grounded in a social conception promoting universalism and equality. The French health-care system is based on compulsory social insurance funded by social contributions, co-administered by workers' and employers' organisations under State control and driven by highly redistributive financial transfers. This system is described frequently as the French model. In this paper, the first in The Lancet's Series on France, we challenge conventional wisdom about health care in France. First, we focus on policy and institutional transformations that have affected deeply the governance of health care over past decades. We argue that the health system rests on a diversity of institutions, policy mechanisms, and health actors, while its governance has been marked by the reinforcement of national regulation under the aegis of the State. Second, we suggest the redistributive mechanisms of the health insurance system are impeded by social inequalities in health, which remain major hindrances to achieving objectives of justice and solidarity associated with the conception of health care in France. ; Depuis 1945, les politiques de santé en France s’appuient sur une conception sociale s’inspirant de deux principes : l’universalisme et l’égalité. Le système de santé français repose en effet sur un système de sécurité sociale obligatoire et fortement redistributif, financé par les contributions sociales et co-administré par les organisations patronales et salariales, sous le contrôle de l’Etat. Ce système est fréquemment désigné comme le « modèle français ». Dans cet article, le premier du numéro spécial du Lancet sur la France, nous remettons en question quelques idées reçues sur l’accès à la santé en France. Dans un premier temps, nous ouvrons la réflexion sur les transformations politiques et institutionnelles qui ont affecté la gouvernance de la santé au cours des dernières décennies. Nous montrons d’une part que le système de santé, loin d’être uniforme, repose sur une diversité d’institutions, mécanismes et acteurs des politiques de santé, d’autre part que la gouvernance de la santé a été marquée par une tendance au renforcement du rôle régulateur de l’Etat. Dans un second temps, nous suggérons que les mécanismes de redistribution du système d’assurance maladie sont bien actifs, mais que leur efficacité reste entravée par les inégalités sociales de santé, lesquelles constituent des obstacles majeurs à la réalisation des objectifs de justice et de solidarité qui sont au cœur de la conception sociale de la santé en France.
Published: 2016

27. Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study

Author: Caroline Solas, Isabelle Poizot-Martin, Eric Bellissant, Lionel Piroth, Patrizia Carrieri, Jade Ghosn, Marc Bourlière, Philippe Colson, Jean-Michel Molina, Alain Renault, Rodolphe Garraffo, Philippe Halfon, Laurent Alric, Alissa Naqvi, Département de Recherche CLinique, CISIH-Sud, Hôpital Sainte-Marguerite, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale ( SESSTIM - U912 INSERM - AMU - IRD ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Institut de Recherche pour le Développement ( IRD ) -Aix Marseille Université ( AMU ), Department of clinical and biological pharmacology and pharmacovigilance, CHU Pontchaillou [Rennes], Centre d'Investigation Clinique [Rennes] ( CIC ), Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Service de pharmacologie, Hôpital Pasteur [Nice] ( CHU ) -CHU Nice, Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes ( URMITE ), Institut de Recherche pour le Développement ( IRD ) -Aix Marseille Université ( AMU ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -IFR48, INSB-INSB-Centre National de la Recherche Scientifique ( CNRS ), Département d'infectiologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Agroécologie [Dijon], Institut National de la Recherche Agronomique ( INRA ) -Université de Bourgogne ( UB ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement, Service de Pharmacocinétique et de Toxicologie, Assistance Publique - Hôpitaux de Marseille ( APHM ) - Hôpital de la Timone [CHU - APHM] ( TIMONE ), Centre de Recherches en Oncologie biologique et Oncopharmacologie ( CRO2 ), Aix Marseille Université ( AMU ) - Hôpital de la Timone [CHU - APHM] ( TIMONE ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Service de Pharmacologie, Service d'hépato-gastro-entérologie, Assistance Publique - Hôpitaux de Marseille ( APHM ), Internal Medicine and Infectious Diseases Department, European Hospital and Alphabio Laboratory, Infection à VIH, réservoirs, diversité génétique et résistance aux antirétroviraux (ARV) ( EA 7327 ), Université Paris Descartes - Paris 5 ( UPD5 ), Pharmacochimie et Pharmacologie Pour le Développement ( PHARMA-DEV ), Université Toulouse III - Paul Sabatier ( UPS ), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut de Recherche pour le Développement (IRD)-Centre National de la Recherche Scientifique ( CNRS ), Service de Maladies Infectieuses [Nice], Observatoire Régional de la Santé Provence Alpes Côte d'Azur, ORS PACA, Service des Maladies Infectieuses et Tropicales [CHU Saint Louis], Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Génétique et Ecologie des Virus, Génétique des Virus et Pathogénèse des Maladies Virales, Université Paris Diderot - Paris 7 ( UPD7 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U912 INSERM - Aix Marseille Univ - IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'Immuno-hématologie clinique [Hôpital Sainte Marguerite - APHM], Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Pasteur [Nice] (CHU), Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes (URMITE), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR48, Institut des sciences biologiques (INSB-CNRS)-Institut des sciences biologiques (INSB-CNRS)-Centre National de la Recherche Scientifique (CNRS), Hôpital de la Timone [CHU - APHM] (TIMONE), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre de Recherches en Oncologie biologique et Oncopharmacologie (CRO2), Aix Marseille Université (AMU)- Hôpital de la Timone [CHU - APHM] (TIMONE)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'hépatologie et de gastroentérologie [Hôpital Saint-Joseph - Marseille], Aix Marseille Université (AMU)-Hôpital Saint-Joseph [Marseille], Hôpital Européen [Fondation Ambroise Paré - Marseille], Infection à VIH, réservoirs, diversité génétique et résistance aux antirétroviraux (ARV) (EA 7327), Université Paris Descartes - Paris 5 (UPD5), Service de Médecine Interne - Immunologie Clinique [AP-HP Bicêtre], AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Pharmacochimie et Biologie pour le Développement (PHARMA-DEV), Institut de Recherche pour le Développement (IRD)-Institut de Chimie de Toulouse (ICT), Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Hôpital Archet 2 [Nice] (CHU), Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille] (ORS PACA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), French National Agency for Research on AIDS and Viral Hepatitis (ANRS), Institut de Recherche pour le Développement (IRD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU), Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud )-Assistance Publique - Hôpitaux de Marseille (APHM), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), INSB-INSB-Centre National de la Recherche Scientifique (CNRS), Institut de Recherche pour le Développement (IRD)-Institut de Chimie de Toulouse (ICT-FR 2599), Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC), Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse], Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Diderot - Paris 7 (UPD7), Hôpital Pasteur [Nice] (CHU)-Centre Hospitalier Universitaire de Nice (CHU Nice), Institut National de la Recherche Agronomique (INRA)-Université de Bourgogne (UB)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement, Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Assistance Publique - Hôpitaux de Marseille (APHM), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), French National Agency for Research on AIDS and Viral Hepatitis(ANRS), Jonchère, Laurent, and Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP)
Subjects: Male, HIV Infections, Hepacivirus, Pharmacology, Gastroenterology, Polyethylene Glycols, chemistry.chemical_compound, 0302 clinical medicine, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Clinical endpoint, boceprevir, Pharmacology (medical), 030212 general & internal medicine, Univariate analysis, Coinfection, virus diseases, Middle Aged, Recombinant Proteins, 3. Good health, [ SDV.MHEP.MI ] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Treatment Outcome, Infectious Diseases, [SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Drug Therapy, Combination, Female, 030211 gastroenterology & hepatology, medicine.drug, Adult, medicine.medical_specialty, Genotype, Proline, direct acting antiviral drug, Antiviral Agents, 03 medical and health sciences, Boceprevir, Internal medicine, Ribavirin, medicine, Humans, Adverse effect, HCV retreatment, business.industry, Interferon-alpha, [ SDV.SP.PHARMA ] Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, Raltegravir, HIV/HCV coinfection, Atazanavir, Regimen, chemistry, HIV-1, [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, business
Abstract: International audience; Background: Scarce data exist on the efficacy and safety of the PEGylated-interferon/ribavirin/boceprevir regimen in HIV/HCV-coinfected patients who failed to respond to PEGylated-interferon/ribavirin treatment.Objectives: To evaluate the efficacy and safety of this drug regimen and the impact of the addition of boceprevir(BOC) on atazanavir (ATV) or raltegravir (RAL) pharmacokinetic parameters in a subgroup of patients.Methods: In this single-arm phase 2 trial, HIV-1/HCV-genotype-1-coinfected patients received PEGylated-interferonα2b (1.5 μg/kg/week)+ ribavirin (800–1400 mg/day) alone until W4 and with BOC(800 mgTID) until W48. Based on virologic response at W8, the three drugs were stopped or PEGylated-interferon/ribavirin was continued alone until W72. The primary endpoint was SVR at W24 off-therapy (SVR24). Results: 64 patients were included. SVR24 was achieved in 53% of patients (CI90%: 43–63%) and in 90% of previous relapsers. In univariate analysis, SVR24 was associated with response to previous HCV treatment, HCV-1b subtype, HCV-RNA decline, ribavirin-Ctrough at W4, and HCV-RNA at W8 but not to fibrosis score, IL28B genotype, or boceprevir-Ctrough at W8. In multivariate analysis, SVR24 remained associated with response to previous HCV treatment [non-responders versus null responders: OR = 5.0(1.3–20.0); relapsers vs. null responders: OR = 28.8(4.9–169.5)]. HCV treatment was discontinued for adverse events in 17% of patients. A 51% decrease in ATV/r-AUC0–8 h (p \textless 0.01) and a 57% increase in RAL-AUC0–8 h (p \textless 0.01) were observed, although atazanavir/r or raltegravir did not affect BOC-AUC0–8 h significantly. The ATV mean Cthrough fell from 763.8 ng/mL (CI 95%: 230.3–1297.3) without BOC to 507.7 ng/mL (CI 95%: 164–851.4) with BOC.Conclusions: Boceprevir-based regimen demonstrated a high SVR24 rate in treatment-experienced HIV-HCV genotype-1-coinfected relapsers.
Published: 2016

28. Benefits of Direct Colposcopic Vision for Optimal LLETZ Procedure: A Prospective Multicenter Study

Author: Didier Riethmuller, Julien Mancini, Claire Caradec, Jean-Luc Brun, Xavier Carcopino, Sébastien Henno, Vincent Lavoué, Lise Preaubert, Julien Chevreau, Anne Mendel, Aubert Agostini, Gery Lamblin, Adelaide Jarniat, Julia Villeret, Jean Gondry, Angélique Bryand, Serge Douvier, Anthony Atallah, Jean-Jacques Baldauf, Hajanarina Rakotomahenina, Hôpital Nord [CHU - APHM], Transporteurs membranaires, chimioresistance et drug-design ( TMCD2 ), Aix Marseille Université ( AMU ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale ( SESSTIM ), Institut de Recherche pour le Développement ( IRD ) -Aix Marseille Université ( AMU ) -ORS PACA-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Institut Paoli Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Biostatistique et technologies de l'information et de la communication (BioSTIC) - [Hôpital de la Timone - APHM] ( BiosTIC ), Institut de Recherche pour le Développement ( IRD ) -Aix Marseille Université ( AMU ) -ORS PACA-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Institut de Recherche pour le Développement ( IRD ) -Aix Marseille Université ( AMU ) -ORS PACA-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Aix Marseille Université ( AMU ) -Assistance Publique - Hôpitaux de Marseille ( APHM ) - Hôpital de la Timone [CHU - APHM] ( TIMONE ), Hôpital Femme Mère Enfant [CHU - HCL] ( HFME ), Hospices Civils de Lyon ( HCL ), Université Nice Sophia Antipolis - Faculté de Médecine ( UNS UFR Médecine ), Université Nice Sophia Antipolis ( UNS ), Université Côte d'Azur ( UCA ) -Université Côte d'Azur ( UCA ), Service de gynécologie–obstétrique, CHU Strasbourg-Hôpital de Hautepierre [Strasbourg], CHU Pontchaillou [Rennes], UFR des Sciences de Santé (Université de Bourgogne), Université de Bourgogne ( UB ), Service de Gynécologie Obstétrique, Médecine Foetale et Stérilité Conjugale - Chirurgie Gynécologie et Oncologique [CHU de Dijon], Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Service de gynécologie, Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Saint-Jacques, department of pathology, university hospital, parakou, Service de gynécologie-obstétrique [Hôpital Nord - APHM], Aix Marseille Université ( AMU ) -Assistance Publique - Hôpitaux de Marseille ( APHM ) - Hôpital Nord [CHU - APHM], Institut méditerranéen de biodiversité et d'écologie marine et continentale ( IMBE ), Université d'Avignon et des Pays de Vaucluse ( UAPV ) -Aix Marseille Université ( AMU ) -Institut de recherche pour le développement [IRD] : UMR237-Centre National de la Recherche Scientifique ( CNRS ), Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U912 INSERM - Aix Marseille Univ - IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Paoli-Calmettes, Biostatistique et technologies de l'information et de la communication (BioSTIC) - [Hôpital de la Timone - APHM] (BiosTIC ), Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Hôpital Femme Mère Enfant [CHU - HCL] (HFME), Hospices Civils de Lyon (HCL), Service de Gynécologie et Obstétrique [Rennes], Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-CHU Pontchaillou [Rennes]-Hôpital Sud, Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)-Hôpital Saint-Jacques, Transporteurs membranaires, chimioresistance et drug-design (TMCD2), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de Recherche pour le Développement (IRD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU), Université Nice Sophia Antipolis - Faculté de Médecine (UNS UFR Médecine), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA), Université de Bourgogne (UB), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques, Hôpital Nord [CHU - APHM]-Assistance Publique - Hôpitaux de Marseille (APHM)-Aix Marseille Université (AMU), Institut méditerranéen de biodiversité et d'écologie marine et continentale (IMBE), Avignon Université (AU)-Aix Marseille Université (AMU)-Institut de recherche pour le développement [IRD] : UMR237-Centre National de la Recherche Scientifique (CNRS), Université Nice Sophia Antipolis (1965 - 2019) (UNS), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital Nord [CHU - APHM], Hôpital de la Timone [CHU - APHM] (TIMONE)-Assistance Publique - Hôpitaux de Marseille (APHM), and Auquier, Pascal
Subjects: Adult, medicine.medical_specialty, Pathology, Electrosurgery, medicine.medical_treatment, [SDV]Life Sciences [q-bio], [ SDV.MHEP.PSM ] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, [SDV.MHEP.PSM] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, [SHS.PSY]Humanities and Social Sciences/Psychology, Cervical intraepithelial neoplasia, [SHS.PSY] Humanities and Social Sciences/Psychology, 03 medical and health sciences, [ SHS.PSY ] Humanities and Social Sciences/Psychology, 0302 clinical medicine, Medicine, [ SHS.ECO ] Humanities and Social Sciences/Economies and finances, Humans, 030212 general & internal medicine, Prospective Studies, [SHS.ECO] Humanities and Social Sciences/Economics and Finance, Prospective cohort study, Cervix, Fixation (histology), Colposcopy, Intraepithelial neoplasia, 030219 obstetrics & reproductive medicine, medicine.diagnostic_test, business.industry, Obstetrics and Gynecology, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, General Medicine, [SHS.ECO]Humanities and Social Sciences/Economics and Finance, medicine.disease, Uterine Cervical Dysplasia, 3. Good health, Surgery, medicine.anatomical_structure, Treatment Outcome, Multicenter study, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, Quality of Life, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Female, business
Abstract: International audience; Objective The aim of the study was to assess whether direct colposcopic ă vision (DCV) of the cervix during large loop excision of the ă transformation zone (LLETZ) is associated with a decrease in the volume ă and dimensions of specimens or affects margin status at histology. ă Materials and Methods A prospective multicenter observational study of ă 216 women who underwent LLETZ for grades 2 and 3 cervical ă intraepithelial neoplasia was conducted. The volume and dimensions ă (circumference, length, and thickness) of the surgical specimens were ă measured before fixation. Data were compared according to the use of ă colposcopy during LLETZ. The following 3 groups were considered: LLETZ ă performed without colposcopy (n = 91), LLETZ performed immediately after ă colposcopy (n = 51), and LLETZ performed under DCV (n = 74). ă Results Patient characteristics were comparable with regard to age, ă parity, history of excision, indication of the procedure, and the size ă of the cervix. We found a significant decrease in all dimensions of the ă specimens obtained under DCV (p < .001). Margin status was not affected. ă After adjusting for confounders, the mean volumes were significantly ă lower in the DCV group (adjusted mean difference = -0.66 mL; 95% CI = ă -1.17 to -0.14). The probability that negative margins would be achieved ă together with the attainment of a volume less than 5 mL and a thickness ă less than 10 mm was the highest in the DCV group (adjusted OR = 2.80; ă 95% CI = 1.13 to 6.90). ă Conclusions Direct colposcopic vision is associated with a significant ă decrease in the volume and in all dimensions of LLETZ specimens with no ă compromise in the margin status.
Published: 2015

29. Correcting for heterogeneity and non‐comparability bias in multicenter clinical trials with a rescaled random‐effect excess hazard model

Author: Juste A. Goungounga, Nathalie Grafféo, Hadrien Charvat, Roch Giorgi, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Registre Bourguignon des Cancers Digestifs, Lipides - Nutrition - Cancer (U866) (LNC), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA)-Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA)-Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre de Recherches sur l'Action Politique en Europe (ARENES), Université de Rennes (UR)-Institut d'Études Politiques [IEP] - Rennes-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Centre National de la Recherche Scientifique (CNRS), Recherche sur les services et le management en santé (RSMS), Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université de Rennes (UR), École des Hautes Études en Santé Publique [EHESP] (EHESP), Département Méthodes quantitatives en santé publique (METIS), Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille] (ORS PACA), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Juntendo University Hospital [Tokyo], Assistance Publique - Hôpitaux de Marseille (APHM), Canceropple Provence-Alpes-Cpte d'Azur, Institut National Du Cancer, Conseil Regional Provence-Alpes-Cpte d'Azur, Canceropple PACA, Conseil Regional PACA, and Internationale
Subjects: Statistics and Probability, Net survival, Life tables, [SDV.CAN]Life Sciences [q-bio]/Cancer, General Medicine, Heterogeneity, Statistics, Probability and Uncertainty, Excess hazard model, Cancer
Abstract: International audience; In the presence of competing causes of event occurrence (e.g., death), the interest might not only be in the overall survival but also in the so-called net survival, that is, the hypothetical survival that would be observed if the disease under study were the only possible cause of death. Net survival estimation is commonly based on the excess hazard approach in which the hazard rate of individuals is assumed to be the sum of a disease-specific and expected hazard rate, supposed to be correctly approximated by the mortality rates obtained from general population life tables. However, this assumption might not be realistic if the study participants are not comparable with the general population. Also, the hierarchical structure of the data can induces a correlation between the outcomes of individuals coming from the same clusters (e.g., hospital, registry). We proposed an excess hazard model that corrects simultaneously for these two sources of bias, instead of dealing with them independently as before. We assessed the performance of this new model and compared it with three similar models, using extensive simulation study, as well as an application to breast cancer data from a multicenter clinical trial. The new model performed better than the others in terms of bias, root mean square error, and empirical coverage rate. The proposed approach might be useful to account simultaneously for the hierarchical structure of the data and the non-comparability bias in studies such as long-term multicenter clinical trials, when there is interest in the estimation of net survival.
Published: 2023

30. Design of a national and regional survey among French general practitioners and method of the first wave of survey dedicated to vaccination

Author: R. Sebbah, Arnaud Gautier, Céline Pulcini, M. Le Maréchal, Lisa Fressard, E. Agamaliyev, Patrick Peretti-Watel, F. Mikol, Pierre Verger, Fanny Collange, Maladies chroniques, santé perçue, et processus d'adaptation (APEMAC), Université Paris Descartes - Paris 5 (UPD5)-Université de Lorraine (UL), Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U912 INSERM - Aix Marseille Univ - IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de Recherche pour le Développement (IRD) Marseille (IRD Marseille), Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille] (ORS PACA), Union régionale des professionnels de santé - médecins libéraux PACA (URPS-ML PACA), Direction de la recherche, des études, de l'évaluation et des statistiques (Ministère des Affaires sociales, de la Santé et des Droits des femmes) (DREES), Institut National de Prévention et d'Education pour la Santé (INPES), Service des Maladies Infectieuses et Tropicales [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), REseau national d'Investigation clinique en VACcinologie (REIVAC), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôtel-Dieu-Groupe hospitalier Broca-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de Gestion des Essais de Produits de Santé (CeNGEPS), Maladies chroniques, santé perçue, et processus d'adaptation. Approches épidémiologiques et psychologiques. ( APEMAC - EA 4360 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Université de Lorraine ( UL ), Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale ( SESSTIM ), Institut de Recherche pour le Développement ( IRD ) -Aix Marseille Université ( AMU ) -ORS PACA-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Institut de Recherche pour le Développement (IRD) Marseille ( IRD Marseille ), Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille] ( ORS PACA ), Union régionale des professionnels de santé - médecins libéraux PACA ( URPS-ML PACA ), Direction de la recherche, des études, de l'évaluation et des statistiques (Ministère des Affaires sociales, de la Santé et des Droits des femmes) ( DREES ), Institut National de Prévention et d'Education pour la Santé ( INPES ), Centre Hospitalier Régional Universitaire de Nancy ( CHRU Nancy ), REseau national d'Investigation clinique en VACcinologie ( REIVAC ), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Cochin [AP-HP]-Hôtel-Dieu-Groupe hospitalier Broca-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de Gestion des Essais de Produits de Santé (CeNGEPS), Centre National de Gestion des Essais de Produits de Santé (CeNGEPS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe hospitalier Broca-Hôtel-Dieu-CHU Cochin [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), and Institut de Recherche pour le Développement (IRD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU)
Subjects: Male, Research design, Questionnaires, Cross-sectional study, MESH : Aged, MESH: Health Care Surveys, MESH : General Practitioners, MESH : Sampling Studies, 0302 clinical medicine, MESH : Cross-Sectional Studies, Surveys and Questionnaires, MESH : Female, 030212 general & internal medicine, Practice Patterns, Physicians', MESH : Physician's Role, Response rate (survey), MESH: Aged, Vaccines, 0303 health sciences, MESH: Middle Aged, Vaccination, MESH: Research Design, Professional Practice, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, MESH: Physician's Role, Middle Aged, MESH : Adult, MESH : Research Design, MESH: Interviews as Topic, 3. Good health, MESH: General Practitioners, MESH : Professional Practice, Infectious Diseases, MESH: Internet, Research Design, Global Positioning System, Female, France, MESH : Internet, MESH : Surveys and Questionnaires, Adult, medicine.medical_specialty, Attitude of Health Personnel, MESH : Male, Médecins généralistes, MESH: Attitude of Health Personnel, education, MESH: Professional Practice, Sample (statistics), Sampling Studies, General practitioner, MESH: Telephone, Interviews as Topic, 03 medical and health sciences, MESH: Cross-Sectional Studies, MESH: Sampling Studies, General Practitioners, medicine, Humans, MESH : Middle Aged, MESH : Health Care Surveys, MESH: Surveys and Questionnaires, Physician's Role, MESH : France, Aged, Internet, MESH: Humans, 030306 microbiology, business.industry, MESH : Humans, Family physician, MESH: Adult, MESH: Vaccination, MESH : Vaccines, MESH: Male, Telephone, MESH: Vaccines, MESH: France, Cross-Sectional Studies, MESH : Practice Patterns, Physicians', Telephone interview, Vaccination policy, MESH : Vaccination, Sample size determination, Health Care Surveys, Family medicine, MESH : Interviews as Topic, MESH: Practice Patterns, Physicians', [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, MESH : Telephone, business, MESH: Female, MESH : Attitude of Health Personnel
Abstract: Objectives France is currently facing a vaccine-hesitancy crisis. We conducted a questionnaire-based telephone interview with a large sample of general practitioners (GPs) as they play a crucial role in the vaccination process. Our main objectives were to study the GPs’ vaccination behaviors when it comes to their own vaccination and that of their relatives, and the vaccine recommendations made to their patients. We also aimed to understand their opinion related to the severity of vaccine-preventable diseases and to assess their trust in various sources of information. Finally, we enquired about their opinion in terms of vaccination-related tools that could help them in their daily practice. The article aimed to present the design of this panel and survey. Patients and methods Four samples of GPs (one national and three regional) were selected among all the French GPs (metropolitan France) using random sampling. Five cross-sectional surveys should be conducted with that panel. The mean targeted sample size is 2350 GPs for each survey. The survey dedicated to vaccination was conducted by telephone or on the Internet. Results GPs were included in the survey between December 2013 and February 2014. The national sample included 1582 GPs (response rate: 46%) and the three regional samples included 1297 GPs (response rate: 44%). The survey dedicated to vaccination was conducted between April and July 2014; the national sample response rate was 92% (1582/1712). Conclusion The results of the first wave of surveys, conducted on a large sample of French GPs, provide important information to guide the French vaccination policy.
Published: 2015

31. Characteristics of patients and physicians correlated with regular influenza vaccination in patients treated for type 2 diabetes: a follow-up study from 2008 to 2011 in southeastern France

Author: Céline Pulcini, Pierre Verger, Ludovic Casanova, Sébastien Cortaredona, Patrick Peretti-Watel, Odile Launay, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale ( SESSTIM ), Institut de Recherche pour le Développement ( IRD ) -Aix Marseille Université ( AMU ) -ORS PACA-Institut National de la Santé et de la Recherche Médicale ( INSERM ), ORS PACA, REseau national d'Investigation clinique en VACcinologie ( REIVAC ), Centre National de Gestion des Essais de Produits de Santé (CeNGEPS)-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Groupe hospitalier Broca-Hôtel-Dieu-CHU Cochin [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP), Maladies chroniques, santé perçue, et processus d'adaptation. Approches épidémiologiques et psychologiques. ( APEMAC - EA 4360 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Université de Lorraine ( UL ), Service des Maladies Infectieuses et Tropicales [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy ( CHRU Nancy ), CIC Cochin Pasteur ( CIC 1417 ), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Cochin [AP-HP]-Hôtel-Dieu-Université Paris Descartes - Paris 5 ( UPD5 ) -Groupe hospitalier Broca-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U912 INSERM - Aix Marseille Univ - IRD), Institut de Recherche pour le Développement (IRD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU), REseau national d'Investigation clinique en VACcinologie (REIVAC), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôtel-Dieu-Groupe hospitalier Broca-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de Gestion des Essais de Produits de Santé (CeNGEPS), Maladies chroniques, santé perçue, et processus d'adaptation (APEMAC), Université Paris Descartes - Paris 5 (UPD5)-Université de Lorraine (UL), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), CIC Cochin Pasteur (CIC 1417), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôtel-Dieu-Université Paris Descartes - Paris 5 (UPD5)-Groupe hospitalier Broca-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de Gestion des Essais de Produits de Santé (CeNGEPS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe hospitalier Broca-Hôtel-Dieu-CHU Cochin [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Cochin [AP-HP]-Hôtel-Dieu-Université Paris Descartes - Paris 5 (UPD5)-Groupe hospitalier Broca-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de Gestion des Essais de Produits de Santé (CeNGEPS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe hospitalier Broca-Hôtel-Dieu-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe hospitalier Broca-Université Paris Descartes - Paris 5 (UPD5)-Hôtel-Dieu-Hôpital Cochin [AP-HP]
Subjects: Male, Pediatrics, MESH : Aged, Type 2 diabetes, Care management, Logistic regression, MESH: Influenza Vaccines, MESH: Aged, 80 and over, MESH : Diabetes Mellitus, Type 2, Epidemiology, MESH : Socioeconomic Factors, MESH: Physicians, MESH : Female, MESH : Influenza, Human, Reimbursement, Aged, 80 and over, MESH: Aged, MESH: Middle Aged, MESH: Influenza, Human, Age Factors, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, General Medicine, MESH: Follow-Up Studies, Middle Aged, MESH : Adult, 3. Good health, Vaccination, Infectious Diseases, Influenza Vaccines, MESH: Young Adult, Cohort, Female, epidemiology, multilevel analysis, France, patient, MESH: Diabetes Mellitus, Type 2, Adult, Microbiology (medical), medicine.medical_specialty, MESH: Socioeconomic Factors, diabetes mellitus type 2, Adolescent, Influenza vaccine, MESH : Male, MESH : Physicians, MESH : Young Adult, determinant, Young Adult, Physicians, Diabetes mellitus, MESH : Adolescent, Influenza, Human, medicine, Humans, MESH : Middle Aged, MESH : Aged, 80 and over, MESH : France, Aged, MESH: Adolescent, MESH: Age Factors, MESH: Humans, business.industry, MESH : Humans, MESH: Adult, MESH : Follow-Up Studies, MESH: Vaccination, medicine.disease, vaccination, MESH: Male, MESH : Influenza Vaccines, MESH: France, Diabetes Mellitus, Type 2, Socioeconomic Factors, MESH : Vaccination, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, MESH : Age Factors, influenza vaccine, business, MESH: Female, Follow-Up Studies
Abstract: International audience; We studied a cohort of 110 823 patients treated with oral hypoglycaemic agents for type 2 diabetes in southeastern France from 1 January 2008 to 31 December 2011, to identify influenza vaccination coverage trends and the patient and physician correlates of influenza vaccine (IFV) uptake. We used French national health insurance fund (NHIF) databases to identify these patients and collect data on their IFV reimbursement claims (IFVC) and patient and physician characteristics. We used multilevel multivariate polytomous logistic regressions to test the correlates of IFVC. Between 2008 and 2011 the annual IFVC rate varied from 33.7% to 32.3% in the 18-64 age group and from 69.5% to 61.1% in the 65 + age group, among whom we saw a clear trend towards reduced vaccination after 2008. In the younger group, the probability of regular vaccination each year from 2008 to 2011 increased with diabetes severity and duration, comorbidities, and the number of general practitioner and nurse visits; it was higher among patients seeing endocrinologists and lower among low-income patients than in other patients. In the older group, there was no association with either diabetes severity or physician specialty. These results suggest different patterns of correlates of influenza vaccination according to age. Endocrinologists might help to improve IFV uptake in the younger group of patients with type 2 diabetes. Communication strategies regarding influenza vaccination should be adapted to age, and collaboration between healthcare professionals should be reinforced to achieve vaccination objectives for these patients.
Published: 2015

32. Scaling up combined community-based HIV prevention interventions targeting truck drivers in Morocco: effectiveness on HIV testing and counseling

Author: Himmich, Hakima, Ouarsas, Lahoucine, Hajouji, Fatima Zahra, Lions, Caroline, Roux, Perrine, Carrieri, Patrizia, Moroccan Association for the Fight against AIDS, ALCS, Observatoire Régional de la Santé Provence Alpes Côte d'Azur, ORS PACA, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U912 INSERM - Aix Marseille Univ - IRD), Institut de Recherche pour le Développement (IRD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU), and Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille] (ORS PACA)
Subjects: Counseling, COUNTRIES, Infectious Diseases, Sexual transmission, IMPACT, INFECTION, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, Community interventions, Truck drivers, FEMALE SEX WORKERS, SOUTH-INDIA, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, HIV testing
Abstract: International audience; Background: Truck drivers constitute an important bridging group in the HIV epidemic in Morocco. This study examined the effect of a community-based educational intervention in Morocco on HIV testing and counseling, in representative samples of truck drivers before (2007) and after (2012) the intervention. Methods: Face-to-face structured interviews, adapted from UNAIDS documents, collected data on socio-demographic characteristics, HIV testing and counseling, and HIV risk behaviors in both the 2007 and 2012 surveys. Information about exposure to the intervention was also collected in the latter. Individuals exposed to the intervention were compared with those unexposed (i.e. unexposed in 2012, and all the 2007 pre-intervention sample). Results: The 2012 group included 459 men with a median [IQR] age of 38 [31-44] years, 53% of whom reported exposure to the educational intervention. The percentage of participants tested for HIV and receiving HIV counseling in the last 12 months, was significantly higher in the 2012 group (29.6% vs 4.3% in 2007). Data from the 2012 survey confirmed a significant positive trend between being HIV tested and receiving counseling and the number of times a participant was exposed to the intervention (once: (OR = 5.17(2.38-11.25)), twice or more (OR = 19.16(10.33 - 35.53)). These results were confirmed after adjustment for employment, knowledge that the HIV test results would remain confidential, inconsistent condom use with occasional partners or sex workers, and when including individuals from 2007 considered unexposed. Conclusions: Community-based educational interventions targeting truck drivers can be effective in increasing coverage of HIV testing and counseling, particularly if they are repeated and cover a considerable portion of this at-risk population. These results are encouraging for other countries which urgently need to implement prevention interventions for most-at-risk populations. Furthermore, they clearly show the power of community-based organization interventions in settings where resources for HIV prevention remain limited.
Published: 2015

33. Vaccine hesitancy: clarifying a theoretical framework for an ambiguous notion

Author: Patrick Peretti-Watel, Heidi J. Larson, Pierre Verger, Jeremy K. Ward, William S. Schulz, ORS PACA, Vecteurs - Infections tropicales et méditerranéennes (VITROME), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées [Brétigny-sur-Orge] (IRBA), CERMES3 - Centre de recherche Médecine, sciences, santé, santé mentale, société (CERMES3 - UMR 8211 / U988 / UM 7), École des hautes études en sciences sociales (EHESS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), London School of Hygiene and Tropical Medicine (LSHTM), Aix Marseille Université (AMU), Institut Hospitalier Universitaire Méditerranée Infection (IHU Marseille), and Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille] (ORS PACA)
Subjects: medicine.medical_specialty, vaccination behavior, Computer science, Process (engineering), Information Seeking Behavior, Population, Medicine (miscellaneous), computer.software_genre, Information seeking behavior, medicine, Contemporary society, Set (psychology), education, education.field_of_study, [SHS.SOCIO]Humanities and Social Sciences/Sociology, risk behavior, Public health, 3. Good health, Epistemology, Commentary, risk culture, vaccine hesitancy, Position (finance), Data mining, Healthism, computer
Abstract: International audience; Today, according to many public health experts, public confidence in vaccines is waning. The term “vaccine hesitancy” (VH) is increasingly used to describe the spread of such vaccine reluctance. But VH is an ambiguous notion and its theoretical background appears uncertain. To clarify this concept, we first review the current definitions of VH in the public health literature and examine its most prominent characteristics. VH has been defined as a set of beliefs, attitudes, or behaviours, or some combination of them, shared by a large and heterogeneous portion of the population and including people who exhibit reluctant conformism (they may either decline a vaccine, delay it or accept it despite their doubts) and vaccine-specific behaviours. Secondly, we underline some of the ambiguities of this notion and argue that it is more a catchall category than a real concept. We also call into question the usefulness of understanding VH as an intermediate position along a continuum ranging from anti-vaccine to pro-vaccine attitudes, and we discuss its qualification as a belief, attitude or behaviour. Thirdly, we propose a theoretical framework, based on previous literature and taking into account some major structural features of contemporary societies, that considers VH as a kind of decision-making process that depends on people’s level of commitment to healthism/risk culture and on their level of confidence in the health authorities and mainstream medicine.
Published: 2015

34. Management of HIV-related stigma and adherence to HAART: Evidence from a large representative sample of outpatients attending French hospitals (ANRS-EN12-VESPA 2003)

Author: P. Peretti-Watel, B. Spire, J. Pierret, F. Lert, Y. Obadia, null The VESPA Group, Epidémiologie et Sciences Sociales Appliquées à l'Innovation Médicale, Université de la Méditerranée - Aix-Marseille 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Observatoire Régional de la Santé de Provence-Alpes-Cote d'Azur, ORS PACA, CERMES - Centre de recherche Médecine, Science, Santé Société (CERMES - UMR 8169 / U750), Université Paris-Sud - Paris 11 (UP11)-École des hautes études en sciences sociales (EHESS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Epidémiologie, santé publique et environnement professionnel et général: méthodes et applications, Epidémiologie, sciences sociales, santé publique (IFR 69), Université Paris 1 Panthéon-Sorbonne (UP1)-Université Paris-Sud - Paris 11 (UP11)-École des hautes études en sciences sociales (EHESS)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris 1 Panthéon-Sorbonne (UP1)-Université Paris-Sud - Paris 11 (UP11)-École des hautes études en sciences sociales (EHESS)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), (ANRS-EN12-VESPA 2003)., Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille] (ORS PACA), and Kaniewski, Nadine
Subjects: Male, Health (social science), Cross-sectional study, Psychological intervention, HIV Infections, MESH: Family Relations, MESH: Self Disclosure, MESH: Research Support, Non-U.S. Gov't, MESH: Antiretroviral Therapy, Highly Active, 0302 clinical medicine, Antiretroviral Therapy, Highly Active, Medicine, 030212 general & internal medicine, 10. No inequality, Prejudice (legal term), MESH: Middle Aged, MESH: HIV Infections, Middle Aged, MESH: Interpersonal Relations, MESH: Patient Compliance, 3. Good health, Self-disclosure, Female, Family Relations, France, 0305 other medical science, Hiv related stigma, Prejudice, MESH: Prejudice, Adult, medicine.medical_specialty, Self Disclosure, Social Psychology, MEDLINE, Hiv disclosure, 03 medical and health sciences, Interpersonal relationship, MESH: Cross-Sectional Studies, Humans, Interpersonal Relations, Psychiatry, Stereotyping, MESH: Humans, 030505 public health, business.industry, Public Health, Environmental and Occupational Health, MESH: Adult, MESH: Male, MESH: France, Cross-Sectional Studies, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, Patient Compliance, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, MESH: Female
Abstract: This study investigated patterns of HIV disclosure to significant others (parents, siblings, children, other relatives, friends and colleagues) and describe them in terms of socio-demographic background and other characteristics, including experiences of AIDS-related discrimination. It also assessed the relationship between disclosure patterns and adherence to HAART. We used a cross-sectional survey conducted among a national representative sample of 2,932 HIV-infected people recruited in French hospitals. HIV disclosure patterns were both selective and cumulative: disclosure was more frequent for friends and siblings, while concealment prevailed concerning children, other relatives, and colleagues; but patients who disclosed their seropositivity to one significant other were also more likely to disclose it to other significant others. Patients reporting experiences of discrimination from sexual partners were less likely to be highly adherent, and we also found a significant relationship between uncontrolled disclosure and non-adherence. Patients who have opted for concealment probably consider non-adherence and uncontrolled disclosure as competing risks, but among them a significant minority loses on both counts. Counselling provided to HIV-infected people should not separate the adherence and disclosure issues, and adherence interventions should seek to help patients to manage concurrently disclosure/concealment of their seropositivity and its consequences.
Published: 2006

35. An instrument to measure psychosocial determinants of health care professionals’ vaccination behavior: Validation of the Pro-VC-Be questionnaire

Author: Pierre Verger, Lisa Fressard, Anna Soveri, Nicolas Dauby, Angelo Fasce, Linda Karlsson, Stephan Lewandowsky, Philipp Schmid, Eve Dubé, Arnaud Gagneur, Vecteurs - Infections tropicales et méditerranéennes (VITROME), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées [Brétigny-sur-Orge] (IRBA), Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille] (ORS PACA), University of Turku, Université libre de Bruxelles (ULB), Universidade de Coimbra [Coimbra], University of Bristol [Bristol], The University of Western Australia (UWA), Institute of Inorganic Chemistry, Karlsruhe Institute of Technology (KIT), Institut de Chimie Séparative de Marcoule (ICSM - UMR 5257), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM)-Ecole Nationale Supérieure de Chimie de Montpellier (ENSCM), Université de Montpellier (UM), Institut National de Santé Publique du Québec [Canada] (INSPQ), Université de Sherbrooke (UdeS), Centre de recherche du centre hospitalier de l'Université de Sherbrooke (CR CHUS), European Project: 964728,JITSUVAX, Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées (IRBA), and Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Ecole Nationale Supérieure de Chimie de Montpellier (ENSCM)-Institut de Chimie du CNRS (INC)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)
Subjects: Health Knowledge, Attitudes, Practice, COVID-19 Vaccines, Health Personnel, education, Immunology, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Surveys and Questionnaires, Drug Discovery, Humans, [SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology, questionnaire validation, ComputingMilieux_MISCELLANEOUS, vaccination behaviors, Pharmacology, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, Vaccines, Vaccination, COVID-19, vaccine confidence, TeDCog, [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, Health care professionals, Cross-Sectional Studies, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, vaccine hesitancy, Molecular Medicine
Abstract: OBJECTIVES The lack of validated instruments assessing vaccine hesitancy/confidence among health care professionals (HCPs) for themselves, and their patients led us to develop and validate the Pro-VC-Be instrument to measure vaccine confidence and other psychosocial determinants of HCPs’ vaccination behavior among diverse HCPs in different countries.METHODS Cross-sectional survey in October-November 2020 among 1,249 GPs in France, 432 GPs in French-speaking parts of Belgium, and 1,055 nurses in Quebec (Canada), all participating in general population immunization. Exploratory and confirmatory factor analyses evaluated the instrument’s construct validity. We used HCPs’ self-reported vaccine recommendations to patients, general immunization activity, self-vaccination, and future COVID-19 vaccine acceptance to test criterion validity.RESULTS The final results indicated a 6-factor structure with good fit: vaccine confidence (combining complacency, perceived vaccine risks, perceived benefit-risk balance, perceived collective responsibility), trust in authorities, perceived constraints, proactive efficacy (combining commitment to vaccination and self-efficacy), reluctant trust, and openness to patients. The instrument showed good convergent and criterion validity and adequate discriminant validity.CONCLUSIONS This study found that the Pro-VC-Be is a valid instrument for measuring psychosocial determinants of HCPs’ vaccination behaviors in different settings. Its validation is currently underway in Europe among various HCPs in different languages.
Published: 2022

36. The French health pass holds lessons for mandatory COVID-19 vaccination

Author: Jeremy K. Ward, Fatima Gauna, Amandine Gagneux-Brunon, Elisabeth Botelho-Nevers, Jean-Luc Cracowski, Charles Khouri, Odile Launay, Pierre Verger, Patrick Peretti-Watel, Vecteurs - Infections tropicales et méditerranéennes (VITROME), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées [Brétigny-sur-Orge] (IRBA), CERMES3 - Centre de recherche Médecine, sciences, santé, santé mentale, société (CERMES3 - UMR 8211 / U988 / UM 7), École des hautes études en sciences sociales (EHESS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon, Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille] (ORS PACA), and ANR-21-COVR-0038,COVIDIgS,Comparaison du role des anticorps IgA/IgM systémique et muqueux dans la physiopathologie et la sévérité de la COVID-19(2021)
Subjects: [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, COVID-19 Vaccines, SARS-CoV-2, Health Policy, Vaccination, COVID-19, Mandatory Programs, General Medicine, Trust, [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, Mass Vaccination, General Biochemistry, Genetics and Molecular Biology, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, Humans, [SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology, France, Vaccination Hesitancy, ComputingMilieux_MISCELLANEOUS
Abstract: International audience
Published: 2022

37. L’annonce du cancer au diagnostic de Tumeur de vessie non infiltrant le muscle modifie-t-elle la qualité de vie et l’observance des patients ? Données de la cohorte prospective française VICAN

Author: A.D. Bouhnik, Jochen Walz, G. Gravis, Rajae Touzani, J. Campagna, Marc-Karim Bendiane, Géraldine Pignot, Patricia Marino, Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U912 INSERM - Aix Marseille Univ - IRD), Institut de Recherche pour le Développement (IRD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU), Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille] (ORS PACA), and Malbec, Odile
Subjects: Quality of life, Gynecology, medicine.medical_specialty, business.industry, [SDV]Life Sciences [q-bio], Urology, 030232 urology & nephrology, Anxiety, 3. Good health, [SDV] Life Sciences [q-bio], 03 medical and health sciences, 0302 clinical medicine, Non-muscle invasive bladder tumor, Diagnosis, Medicine, 030212 general & internal medicine, business, Cancer
Abstract: Resume Introduction L’information transmise au diagnostic de Tumeur de vessie non infiltrant le muscle (TVNIM) est variable. Or, les patients bien informes sont plus impliques dans les decisions partagees. L’objectif de cette etude etait d’evaluer l’information percue par le patient au moment du diagnostic de TVNIM. Materiel La cohorte francaise VICAN consiste en un echantillon representatif de 4174 patients pris en charge pour un cancer et survivants a 5 ans. Les donnees reportees par les patients ont ete collectees prospectivement par entretiens telephoniques et auto-questionnaires. Parmi les 118 patients pris en charge pour une TVNIM, le terme utilise au diagnostic pour definir la pathologie et l’impact sur la qualite de vie (questionnaires SF12, EORTC-QLQ-C30 et echelle HAD) et sur l’observance (suivi cystoscopique a 1 an selon les donnees du SNIIR-AM) ont ete evalues. Resultats Seuls 26,8 % des patients ont declare avoir entendu le terme “Cancer” a l’annonce du diagnostic de TVNIM. A l’inverse, 73,2 % d’entre eux ont reporte l’utilisation d’autres termes, incluant “Tumeur” (22,0 %), “Polype” (24,8 %) et “Carcinome” (17,1 %). Il n’y avait pas de difference en termes de qualite de vie, physique et mentale, ni d’anxiete ressentie, en fonction du terme utilise. L’observance etait significativement meilleure chez les patients pour qui le mot « Cancer » a ete utilise. Conclusion Trois quarts des patients ayant une TVNIM n’avaient pas integre la notion de “Cancer” au diagnostic. La terminologie utilisee au diagnostic n’influence pas la qualite de vie mais semble impacter l’observance et l’adhesion aux protocoles de soins. Niveau de preuve 3.
Published: 2022

38. Hepatitis B in Senegal: A Successful Infant Vaccination Program but Urgent Need to Scale Up Screening and Treatment (ANRS 12356 AmBASS survey)

Author: Périères, Lauren, Diallo, Aldiouma, Marcellin, Fabienne, Nishimwe, Marie Libérée, Ba, El Hadji, Coste, Marion, Lo, Gora, Halfon, Philippe, Touré Kane, Coumba, Maradan, Gwenaëlle, Carrieri, Patrizia, Diouf, Assane, Shimakawa, Yusuke, Sokhna, Cheikh, Boyer, Sylvie, Bérenger, Cyril, Bousmah, Marwan al Qays, de Seze, Maëlle, Djaogol, Tchadine, Treibich, Carole, Ba, Elhadji, Dièye, Fambaye, Faye, Elhadji Bilal, Ndiaye, Assane, Sow, Mouhamadou Baba, Ndiaye, Anna Julienne Selbé, Ndiour, Samba, Mohamed, Sofiane, Rouveau, Nicolas, Cortès, Maria‐Camila Calvo, Laborde‐Balen, Gabrièle, Audibert, Martine, Fall, Fatou, Gueye, Ibrahima, Lacombe, Karine, Seydi, Moussa, Tuaillon, Edouard, Vray, Muriel, Vecteurs - Infections tropicales et méditerranéennes (VITROME), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées [Brétigny-sur-Orge] (IRBA), Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD), Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut des sciences de la santé publique [Marseille] (ISSPAM), Aix-Marseille Sciences Economiques (AMSE), École des hautes études en sciences sociales (EHESS)-Aix Marseille Université (AMU)-École Centrale de Marseille (ECM)-Centre National de la Recherche Scientifique (CNRS), Institut de Recherche en Santé, de Surveillance Épidémiologique et de Formation [Dakar, Sénégal] (IRESSEF), ALPHABIO - Laboratoire de biologie médicale, Hôpital Européen [Fondation Ambroise Paré - Marseille], Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille] (ORS PACA), Epidémiologie des Maladies Emergentes - Emerging Diseases Epidemiology, Université Paris Cité (UPCité)-Pasteur-Cnam Risques infectieux et émergents (PACRI), Institut Pasteur [Paris] (IP)-Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Université Paris Cité (UPCité)-Institut Pasteur [Paris] (IP)-Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM), ANRS 12356 AmBASS Survey Study Group: Cyril Bérenger, Marwan Al Qays Bousmah, Sylvie Boyer, Patrizia Carrieri, Marion Coste, Maëlle de Seze, Tchadine Djaogol, Gwenaëlle Maradan, Fabienne Marcellin, Carole Treibich, Elhadji Ba, Aldiouma Diallo, Fambaye Dièye, Assane Diouf, Elhadji Bilal Faye, Assane Ndiaye, Lauren Périères, Cheikh Sokhna, Mouhamadou Baba Sow, Coumba Touré Kane, Gora Lo, Anna Julienne Selbé Ndiaye, Samba Ndiour, Philippe Halfon, Sofiane Mohamed, Nicolas Rouveau, Maria-Camila Calvo Cortès, Gabrièle Laborde-Balen, Martine Audibert, Fatou Fall, Ibrahima Gueye, Karine Lacombe, Moussa Seydi, Yusuke Shimakawa, Edouard Tuaillon, Muriel Vray, Lhuillier, Elisabeth, and Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées (IRBA)
Subjects: Adult, Hepatitis B Surface Antigens, Adolescent, Hepatology, Vaccination, Infant, Hepatitis B, [SHS.ECO]Humanities and Social Sciences/Economics and Finance, Senegal, 3. Good health, Young Adult, 03 medical and health sciences, Cross-Sectional Studies, 0302 clinical medicine, Humans, Female, Hepatitis B Vaccines, 030211 gastroenterology & hepatology, 030212 general & internal medicine, [SHS.ECO] Humanities and Social Sciences/Economics and Finance, Child
Abstract: International audience; Senegal introduced the infant hepatitis B virus (HBV) vaccination in 2004 and recently committed to eliminating hepatitis B by 2030. Updated epidemiological data are needed to provide information on the progress being made and to develop new interventions. We estimated the prevalence of hepatitis B surface antigen (HBsAg) in children and adults living in rural Senegal and assessed hepatitis B treatment eligibility. A cross-sectional population-based serosurvey of HBsAg was conducted in 2018-2019 in a large sample (n = 3,118) of residents living in the Niakhar area (Fatick region, Senegal). Individuals positive for HBsAg subsequently underwent clinical and biological assessments. Data were weighted for age and sex and calibrated to be representative of the area's population. Among the 3,118 participants, 206 were HBsAg positive (prevalence, 6.9%; 95% confidence interval [CI], 5.6-8.1). Prevalence varied markedly according to age group in individuals aged 0-4, 5-14, 15-34, and >= 35 years as follows: 0.0% (95% CI, 0.00-0.01); 1.5% (95% CI, 0.0-2.3); 12.4% (95% CI, 9.1-15.6); and 8.8% (95% CI, 6.1-11.5), respectively. Of those subsequently assessed, 50.9% (95% CI, 41.8-60.0) had active HBV infection; 4 (2.9%; 95% CI, 0.9-9.4) were eligible for hepatitis B treatment. Conclusion: In this first population-based serosurvey targeting children and adults in rural Senegal, HBsAg prevalence was very low in the former, meeting the World Health Organization's (WHO) < 1% HBsAg 2020 target; however, it was high in young adults (15-34 years old) born before the HBV vaccine was introduced in 2004. To reach national and WHO hepatitis elimination goals, general population testing (particularly for adolescents and young adults), care, and treatment scale-up need to be implemented.
Published: 2021

39. Hepatitis A and B vaccine uptake and immunisation among men who have sex with men seeking PrEP: a substudy of the ANRS IPERGAY trial

Author: Paul, Le Turnier, Isabelle, Charreau, Audrey, Gabassi, Diane, Carette, Laurent, Cotte, Gilles, Pialoux, Cécile, Tremblay, Bruno, Spire, Marie-Laure, Chaix, Laurence, Meyer, Catherine, Capitant, Constance, Delaugerre, François, Raffi, Jean-Michel, Molina, N, Lorente, Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire de Virologie [CHU Saint-Louis], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris Descartes - Paris 5 (UPD5), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CR CHUM), Centre Hospitalier de l'Université de Montréal (CHUM), Université de Montréal (UdeM)-Université de Montréal (UdeM), Université de Montréal (UdeM), CRSN/Faculté de médecine Université de Montréal, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille] (ORS PACA), Génétique et Ecologie des Virus, Génétique des Virus et Pathogénèse des Maladies Virales, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de maladies infectieuses et tropicales [Saint-Louis], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Cité (UPCité), Génomes, biologie cellulaire et thérapeutiques (GenCellDi (U944 / UMR7212)), Collège de France (CdF (institution))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Centre d’Investigation Clinique de Nantes (CIC Nantes), Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre hospitalier universitaire de Nantes (CHU Nantes), Hopital Saint-Louis [AP-HP] (AP-HP), and Université Sorbonne Paris Cité (USPC)
Subjects: Infectious Diseases, [SDV]Life Sciences [q-bio], Dermatology
Abstract: Vaccination against hepatitis A virus (HAV) and hepatitis B virus (HBV) is recommended in men who have sex with men (MSM). We assessed HAV and HBV vaccine uptake in the non-immune participants and their immunisation during follow-up of the ANRS IPERGAY (Intervention Préventive de l'Exposition aux Risques avec et pour les Gays) pre-exposure prophylaxis (PrEP) trial.During the ANRS IPERGAY trial among MSM (NCT 01473472), vaccination against HAV and HBV was offered free of charge to all non-immune participants at baseline. We assessed anti-HAV IgGs and anti-hepatitis B surface (HBs) antibodies (Abs) at baseline, 1–3 months after each vaccine dose and on the last follow-up visit. Vaccination uptake and immunisation were analysed in non-immune participants with at least 6 months of follow-up after the 1st vaccine dose.A total of 427 MSM with a median age of 34.8 years were analysed. Median follow-up was 2.2 years (Q1–Q3, 1.6–2.9). Absence of anti-HAV IgG at baseline (50.4%, 215/427) was associated with younger age (p=0.0001). Among HAV non-immune participants, 96.1% (197/205) received one or more vaccine doses and 91.0% (172/189) received two vaccine doses. Among HBV non-immune participants, 97.6 % (81/83) received one or more vaccine doses and 78.4% (58/74) received three doses. On the last-visit sample, anti-HAV IgG and anti-HBs Abs were respectively detected in 94.8% (95% CI 90.0% to 97.7%) and 79.6% (95% CI 66.5% to 89.4%) of participants with complete vaccination and in 80.0% (95% CI 51.9% to 95.7%) and 40.0% (95% CI 16.3% to 67.7%) of participants with incomplete vaccination.Vaccine acceptability against HAV and HBV infections was very high in MSM starting PrEP. Immunisation was high in participants with a full vaccination scheme. Physicians must consider PrEP visits as major opportunities to propose and complete HAV and HBV vaccination in at-risk non-immune subjects.
Published: 2022

40. United, can we be stronger? Did French general practitioners in multi-professional groups provide more chronic care follow-up during lockdown?

Author: Anna, Zaytseva, Pierre, Verger, Bruno, Ventelou, Aix-Marseille Sciences Economiques (AMSE), École des hautes études en sciences sociales (EHESS)-Aix Marseille Université (AMU)-École Centrale de Marseille (ECM)-Centre National de la Recherche Scientifique (CNRS), Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille] (ORS PACA), Vecteurs - Infections tropicales et méditerranéennes (VITROME), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées [Brétigny-sur-Orge] (IRBA), French Institute for Public Health Research grant IReSP-LIAAP18-HSR-008, Sud ProvenceAlpes-Cote d'Azur regional council, ANR-17-EURE-0020,AMSE (EUR),Aix-Marseille School of Economics(2017), and ANR-11-IDEX-0001,Amidex,INITIATIVE D'EXCELLENCE AIX MARSEILLE UNIVERSITE(2011)
Subjects: Male, Attitude of Health Personnel, Provider-sponsored organizations, nutritional and metabolic diseases, COVID-19, Middle Aged, [SHS.ECO]Humanities and Social Sciences/Economics and Finance, Long-term care, Cross-Sectional Studies, General practitioners, Chronic Disease, Communicable Disease Control, Humans, Female, France, Follow-Up Studies
Abstract: International audience; Background Given the importance of the continuous follow-up of chronic patients, we evaluated the performance of French private practice general practitioners (GPs) practicing in multi-professional group practices (MGP) regarding chronic care management during the first Covid-19 lockdown in Spring 2020 compared to GPs not in MGP. We consider two outcomes: continuity of care provision for chronic patients and proactivity in contacting these patients. Methods The cross-sectional web questionnaire of 1191 GPs took place in April 2020. We exploit self-reported data on: 1) the frequency of consultations for chronic patients during lockdown compared to their “typical” week before the pandemic, along with 2) GPs’ proactive behaviour when contacting their chronic patients. We use probit and bivariate probit models (adjusted for endogeneity of choice of engagement in MGP) to test whether GPs in MGP had significantly different responses to the Covid-19 crisis compared to those practicing outside MGP. Results Out of 1191 participants (response rate: 43.1%), around 40% of GPs were female and 34% were younger than 50 years old. Regression results indicate that GPs in MGP were less likely to experience a drop in consultations related to complications of chronic diseases (− 45.3%). They were also more proactive (+ 13.4%) in contacting their chronic patients compared to their peers practicing outside MGP. Conclusion We demonstrate that the MGP organisational formula was beneficial to the follow-up of patients with chronic conditions during the lockdown; therefore, it appears beneficial to expand integrated practices, since they perform better when facing a major shock. Further research is needed to confirm the efficiency of these integrated practices outside the particular pandemic setup.
Published: 2022

41. General practitioners' attitude towards cooperation with other health professionals in managing patients with multimorbidity and polypharmacy: A cross-sectional study

Author: Hélène Carrier, Anna Zaytseva, Aurélie Bocquier, Patrick Villani, Martin Fortin, Pierre Verger, Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille] (ORS PACA), Aix-Marseille Université - École de médecine (AMU SMPM MED), Aix-Marseille Université - Faculté des sciences médicales et paramédicales (AMU SMPM), Aix Marseille Université (AMU)-Aix Marseille Université (AMU), Aix-Marseille Sciences Economiques (AMSE), École des hautes études en sciences sociales (EHESS)-Aix Marseille Université (AMU)-École Centrale de Marseille (ECM)-Centre National de la Recherche Scientifique (CNRS), Assistance Publique - Hôpitaux de Marseille (APHM), Unité de coordination en oncogériatrie (UCOG Paca ouest), Université de Sherbrooke (UdeS), DREES (Direction for Research, Studies, Evaluation and Statistics, Ministere des affaires sociales et de la sante (Ministry of Health and Social Services), INPES (National Institute of Prevention and Education for Health), INSERM (National Institute of Health and Medical Research), and ANSM (National Agency for Drug's and Health Produces' Safety)
Subjects: Cross-Sectional Studies, genetic structures, Attitude of Health Personnel, General Practitioners, interprofessional relations, education, pharmacists, Humans, Multimorbidity, polypharmacy, Family Practice, nurse practitioners, [SHS.ECO]Humanities and Social Sciences/Economics and Finance
Abstract: International audience; Background: Cooperation between general practitioners (GPs) and other healthcare professionals appears to help reduce the risk of polypharmacy-related adverse events in patients with multimorbidity.Objectives: To investigate GPs profiles according to their opinions and attitudes about interprofessional cooperation and to study the association between these profiles and GPs’ characteristics.Methods: Between May and July 2016, we conducted a cross-sectional survey of a panel of French GPs about their management of patients with multimorbidity and polypharmacy, focussing on their opinions on the roles of healthcare professionals and interprofessional cooperation. We used agglomerative hierarchical cluster analysis to identify GPs profiles, then multivariable logistic regression models to study their associations with the characteristics of these doctors.Results: 1183 GPs responded to the questionnaire. We identified four profiles of GPs according to their declared attitudes towards cooperation: GPs in the ‘very favourable’ profile (14%) were willing to cooperate with various health professionals, including the delegation of some prescribing tasks to pharmacists; GPs in the ‘moderately favourable’ profile (47%) had favourable views on the roles of health professionals, with the exception for this specific delegation of the task; GPs from the ‘selectively favourable’ profile (27%) tended to work only with doctors; GPs from the ‘non-cooperative’ profile (12%) did not seem to be interested in cooperation. Some profiles were associated with GPs’ ages or participation in continuing medical education.Conclusion: Our study highlights disparities between GPs regarding cooperation with other professionals caring for their patients and suggests ways to improve cooperation.
Published: 2022

42. Pobreza, 'presentismo' y prevención

Author: Tarantini, Clément, Vergelys, Chantal, Peretti-Watel, Patrick, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale ( SESSTIM ), Institut de Recherche pour le Développement ( IRD ) -Aix Marseille Université ( AMU ) -ORS PACA-Institut National de la Santé et de la Recherche Médicale ( INSERM ), ORS PACA, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U912 INSERM - Aix Marseille Univ - IRD), Institut de Recherche pour le Développement (IRD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU), and Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Subjects: Presente, Prévention, Precariedad, Salud, Tabagisme, Précarité, Normes, Norm, Normas, Cigarette Addiction, Autonomy, Présent, Santé, [SHS.SOCIO]Humanities and Social Sciences/Sociology, [ SHS.SOCIO ] Humanities and Social Sciences/Sociology, [SHS.ANTHRO-SE]Humanities and Social Sciences/Social Anthropology and ethnology, Temporalidades, Autonomie, Temporalities, Tabaquismo, Job Insecurity, Prevención, [ SHS.ANTHRO-SE ] Humanities and Social Sciences/Social Anthropology and ethnology, Health, Autonomía, Temporalités
Abstract: International audience; The result of injunctions to take time on its own terms, prevention seems to pay little attention to the plurality of social times, to their contexts of production and enunciation. As health inequalities partly reside in the ability of individuals to respect preventive norms and thus acttoday for their future state of health, and as poverty tends to obstruct projecting oneself into the future, we wished to analyze the positions of people in various precarious situations confronted by prevention discourse and the implementation of their own health projects, while placing the "issue" of temporalities at the heart of our research. Depending on different socioeconomic contexts, available resources, anticipating social ascent or drop in status, preventive standards will not be appropriate and experienced the same way. This article makes it clear that under cover of apparently common demands, driven by the desire to adhere to the norm, diverse motivations and practices in reality obtain, largely influenced by socially differentiated regimes of temporality.; Atiborrada de mandatos que imponen a las personas asirse del tiempo según sus propios cánones, la prevención no parece prestar mayor atención a la pluralidad de los tiempos sociales, ni a sus contextos de producción y de enunciación. Sabemos que las desigualdades sociales en salud residen parcialmente en la capacidad del individuo para poner en práctica las normas preventivas, y por ende para actuar hoy en pos de su salud futura. Sabemos también que la pobreza contribuye a frenar la proyección hacia futuro. Desde esta óptica, analizamos losposicionamientos frente a los discursos preventivos y al manejo de sus propios proyectos en personas que viven diferentes situaciones de precariedad de salud. Asimismo, situamos la "cuestión" de las relaciones temporales en el centro de la investigación. Según los contextossocio-económicos, los recursos movilizables, las perspectivas de ascensión o de desclasamiento social, las normas preventivas no son apropiadas y restituidas del mismo modo. Resulta entonces que, detrás de reivindicaciones aparentemente comunes, impulsadas por el deseo de adherir a la norma, se inscriben en realidad motivaciones y prácticas diversas, profundamente influenciadaspor regímenes temporales socialmente diferenciados.; Pétrie d’injonctions à s’approprier le temps selon ses propres canons, la prévention semble ne prêter que peu d’attention à la pluralité des temps sociaux, ainsi qu’à leurs contextes de production et d’énonciation. Dans la mesure où les inégalités sociales de santé résident en partiedans la capacité de l’individu à mettre en pratique les normes préventives, et donc à agir aujourd’hui pour sa santé de demain, et où la pauvreté contribue à entraver la projection dans un à venir, nous avons souhaité analyser les positionnements de personnes se trouvant dansdifférentes situations de précarité face aux discours préventifs et à l’entreprise de leurs propres projets de santé, tout en plaçant la « question » des rapports au temps au coeur de nos travaux. Aussi, selon les contextes socio-économiques, les ressources mobilisables, les perspectivesd’ascension ou de déclassement social, les normes préventives ne sont pas appropriées et restituées de la même façon. Il ressort de cet article que sous des revendications apparemment communes, impulsées par le désir d’adhérer à la norme, s’inscrivent en réalité des motivations et des pratiques diverses, largement influencées par des régimes de temporalités socialement différenciés.
Published: 2014

43. Travailler après un cancer du sein. Enjeux, contraintes et perspectives

Author: Tarantini , Clément, Gallardo , Lucille, Peretti-Watel , Patrick, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U912 INSERM - Aix Marseille Univ - IRD), Institut de Recherche pour le Développement (IRD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU), Sociologie, philosophie et anthropologie politiques (SOPHIAPOL), Université Paris Nanterre (UPN), Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille] (ORS PACA), Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale ( SESSTIM ), Institut de Recherche pour le Développement ( IRD ) -Aix Marseille Université ( AMU ) -ORS PACA-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Sociologie, philosophie et socio-anthropologie politiques ( SOPHIAPOL ), Université Paris Nanterre ( UPN ), Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille] ( ORS PACA ), and Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Subjects: Employment, [SHS.SOCIO]Humanities and Social Sciences/Sociology, Rémission, Précarité professionnelle, [ SHS.SOCIO ] Humanities and Social Sciences/Sociology, [SHS.ANTHRO-SE]Humanities and Social Sciences/Social Anthropology and ethnology, Emploi, [SHS]Humanities and Social Sciences, [ SHS.ANTHRO-SE ] Humanities and Social Sciences/Social Anthropology and ethnology, Breast cancer, [ SHS ] Humanities and Social Sciences, Disease, Maladie, Job insecurity, Cancer du sein
Abstract: International audience; This paper deals with the consequences of breast cancer on the professional reintegration of 21 women. These women were under the age of 40 at the time of diagnosis and have been questioned 16 to 24 months later. Although they all express the willingness to reengage in the professional world, their life courses testify that their disease induced deep transformations in their professional lives. Through an analysis of interactions between disease and work in the life narratives of these women, this paper contributes to a broader reflection on the understandings of breast cancer and work in our societies, and of the relationship between them.; Le présent article s’intéresse aux conséquences du cancer du sein sur la réinsertion professionnelle de 21 femmes, âgées de moins de 40 ans lors du diagnostic et interrogées de 16 à 24 mois après. Si la volonté d’un réinvestissement dans une vie professionnelle fait l’unanimité, chacun de leurs parcours témoigne des profondes transformations des rapports à la vie professionnelle, induites par la maladie. Dans une analyse mettant en lumière les interactions entre la maladie et le travail dans ces récits de vie, se dessine en filigrane l’inscription des conceptions du cancer du sein et du travail dans nos sociétés, ainsi que leur articulation.
Published: 2014

44. Rate and Predictors of Ineffective HIV Protection in African Men Who Have Sex with Men Taking Pre-Exposure Prophylaxis

Author: Eubanks, August, Coulibaly, Bakary, Dembélé Keita, Bintou, Anoma, Camille, Dah, ter Tiero Elias, Mensah, Ephrem, Maradan, Gwenaëlle, Bourrelly, Michel, Mora, Marion, Riegel, Lucas, Rojas Castro, Daniela, Yaya, Issifou, Spire, Bruno, Laurent, Christian, Sagaon-Teyssier, Luis, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut des sciences de la santé publique [Marseille] (ISSPAM), ARCAD Santé PLUS [Bamako, Mali], Espace Confiance [Abidjan, Côte d’Ivoire], Association African Solidarité [Ouagadougou, Burkina Faso], Centre Muraz [Bobo-Dioulasso, Burkina Faso], Espoir Vie Togo [Lomé, Togo], Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille] (ORS PACA), Coalition PLUS [Pantin, France] (Community Research Laboratory Pantin), Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques et émergentes (TransVIHMI), Institut de Recherche pour le Développement (IRD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), and The COHMSM-PrEP Study Group.
Subjects: Male, Social Psychology, Anti-HIV Agents, [SDV]Life Sciences [q-bio], HIV Infections, Cohort Studies, MESH: Homosexuality, Male, Sexual and Gender Minorities, Community-based research, Burkina Faso, West Africa, Humans, MESH: Burkina Faso, Prospective Studies, MSM, Homosexuality, Male, MESH: Anti-HIV Agents, MESH: Cohort Studies, MESH: Humans, Public Health, Environmental and Occupational Health, HIV, MESH: HIV Infections, PrEP, MESH: Male, MESH: Prospective Studies, MESH: Sexual and Gender Minorities, Infectious Diseases, Pre-Exposure Prophylaxis, MESH: Pre-Exposure Prophylaxis
Abstract: We investigated the rate and predictors of ineffective HIV protection in men who have sex with men (MSM) taking pre-exposure prophylaxis (PrEP) in a prospective cohort study from November 2017 to November 2020 in Mali, Côte d'Ivoire, Burkina Faso, and Togo. MSM had to be 18 years or older and at high risk of HIV infection to participate. They also received a comprehensive sexual health prevention package, including PrEP, in community-based clinics as part of the cohort study. Using socio-behavioral/clinical data, HIV protection during their most recent anal intercourse with a male partner was categorized as effective or ineffective (i.e., incorrect PrEP adherence and no condom use). Seventeen percent (500/2839) of intercourses were ineffectively protected for the 520 study participants. Predictors of ineffective HIV protection included being an event-driven user with financial difficulties, having a high alcohol misuse score, and not being a member of a community association. PrEP programs in West Africa must be tailored to socially vulnerable MSM who struggle to adopt PrEP.En este artículo hemos investigado la proporción y los factores predictivos de la protección ineficaz de VIH en un grupo de hombres, que tienen sexo con hombres (HSH) y que usan la profilaxis pre-exposición (PrEP). Se usaron los datos de un estudio de cohorte prospectivo realizado entre noviembre del 2017 y noviembre del 2020 en Mali, Costa de Marfil, Burkina Faso y Togo. Los participantes son HSH, de 18 años o más, y con alto riesgo de contaminación por el VIH. Estos han recibido un paquete completo de prevención en salud sexual incluyendo la PrEP en clínicas comunitarias como parte del estudio de cohorte. La protección contra el VIH durante la última relación sexual anal con un hombre fue categorizada como eficaz o ineficaz a partir de datos socio-comportamentales/clínicos (i.e. adhesión incorrecta à la PrEP y no utilización del condón). Concerniente a 520 participantes, 17% (500/2839) de las relaciones sexuales fueron protegidas de manera ineficaz. Entre los factores predictivos de la protección ineficaz contra el VIH se encuentran, el uso intermitente de la PrEP asociado a una situación financiera difícil, el consumo de alcohol y no ser miembro de una asociación comunitaria. Los programas de PrEP en África del Oeste, deben adaptarse a los HSH más vulnerables quienes podrían tener más dificultad para adoptar la PrEP.
Published: 2022

45. Risk Prediction Score for Screening Asymptomatic Sexually Transmitted Infections in HIV-positive French Men Who Have Sex with Men (ANRS 9520 DRIVER)

Author: Martin, Duracinsky, Svetlane, Dimi, Maria Patrizia, Carrieri, Issifou, Yaya, Virginie, Villes, Nadia, Valin, Eric, Farfour, Olivier, Chassany, David, Zucman, Epidémiologie Clinique et Evaluation Economique Appliquées aux Populations Vulnérables (ECEVE (U1123 / UMR_S_1123)), Institut National de la Santé et de la Recherche Médicale (INSERM)-AP-HP Hôpital universitaire Robert-Debré [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Cité (UPCité), Unité de recherche clinique en économie de la santé [Paris] (URC Eco), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Hôtel-Dieu [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Patient-Centered Outcomes Research [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Cité (UPCité)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AP-HP Hôpital universitaire Robert-Debré [Paris], Service de Médecine Interne - Immunologie Clinique [AP-HP Bicêtre], AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Service de Médecine Interne [Hôpital Foch, Suresnes] (SMI), Hôpital Foch [Suresnes], Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut des sciences de la santé publique [Marseille] (ISSPAM), Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille] (ORS PACA), CHU Saint-Antoine [AP-HP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
Subjects: Male, MESH: Sexual Behavior, Health (social science), MESH: Humans, MESH: Middle Aged, Social Psychology, Sexual Behavior, [SDV]Life Sciences [q-bio], Sexually Transmitted Diseases, Public Health, Environmental and Occupational Health, HIV Infections, MESH: HIV Infections, Middle Aged, MESH: Male, MESH: Homosexuality, Male, MESH: Sexual and Gender Minorities, Sexual and Gender Minorities, MESH: HIV Seropositivity, HIV Seropositivity, Humans, Homosexuality, Male, MESH: Sexually Transmitted Diseases
Abstract: International audience; Objectives: Asymptomatic sexually transmitted infections (STI) are frequent among men who have sex with men (MSM). Identifying asymptomatic STIs is a crucial issue, not only for secondary but also for primary prevention, as early treatment can reduce transmission risk. We aimed to develop a self-reported predictive score for early identification of asymptomatic STIs. Methods: Participants provided clinical data and completed a self-administered questionnaire including sociodemographic variables and behaviors during the 6 previous months. We used multivariable logistic regression to identify factors associated with asymptomatic STIs. We calculated the accuracy of the model by the non-parametric area (AUC) under the receiver-operating-characteristic (ROC) curve to find the optimal discriminant threshold for screening. Results:A total of 781 HIV-positive MSM were included with a mean age of 46.8 years. Asymptomatic STI prevalence was 13.2%. Detectable plasma HIV RNA (adjusted odds ratio (aOR [95% CI): 2.54 [1.23;5.25]), inconsistent condom use during anal sex (2.20 [1.36;3.56]), group sex (2.00 [1.15;3.45]), during or-genital practices (1.83 [1.12;3.01]), not being in stable relationship (1.70 [1.01;2.66] and an item from a sensation-seeking behavioral scale "I don't like watching porn videos" (1.61 [1.01;2.59] were associated with asymptomatic STI. AUC was 0.7 and with optimal threshold of 0.1082 for this model; sensitivity was 80.4%. Self-reported asymptomatic STI predictive score was built with this threshold according to the 6 factors in the final model. Conclusions: As this predictive score is not designed to be diagnostic, but to provide indications for diagnostic tests, its ease of administration and sensitivity remain the most important features. Its use in clinical practice for early detection of asymptomatic STIs potentially can reinforce STI primary and secondary prevention.
Published: 2022

46. Loss to Follow-Up from HIV Pre-Exposure Prophylaxis Care in Men Who Have Sex with Men in West Africa

Author: August, Eubanks, Bakary, Coulibaly, Bintou Dembélé, Keita, Camille, Anoma, Ter Tiero Elias, Dah, Ephrem, Mensah, Gwenaëlle, Maradan, Michel, Bourrelly, Marion, Mora, Lucas, Riegel, Daniela, Rojas Castro, Issifou, Yaya, Bruno, Spire, Christian, Laurent, Luis, Sagaon-Teyssier, The CohMSM-PrEP Study Group, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut des sciences de la santé publique [Marseille] (ISSPAM), ARCAD Santé PLUS [Bamako, Mali], Espace Confiance [Abidjan, Côte d’Ivoire], Association African Solidarité [Ouagadougou, Burkina Faso], Espoir Vie Togo [Lomé, Togo], Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille] (ORS PACA), Coalition PLUS [Pantin, France] (Community Research Laboratory Pantin), Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques et émergentes (TransVIHMI), Institut de Recherche pour le Développement (IRD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), and The CohMSM-PrEP Study Group
Subjects: Male, Anti-HIV Agents, [SDV]Life Sciences [q-bio], HIV Infections, community-based research, MESH: Homosexuality, Male, Sexual and Gender Minorities, Virology, West Africa, Burkina Faso, key populations, Humans, MESH: Burkina Faso, MSM, Prospective Studies, MESH: Anti-HIV Agents, Homosexuality, Male, MESH: Humans, MESH: HIV Infections, MESH: Follow-Up Studies, PrEP, MESH: Male, MESH: Prospective Studies, MESH: Sexual and Gender Minorities, Infectious Diseases, HIV/AIDS, pre-exposure prophylaxis, Pre-Exposure Prophylaxis, MESH: Pre-Exposure Prophylaxis, Follow-Up Studies
Abstract: International audience; Loss to follow-up (LTFU) from HIV pre-exposure prophylaxis (PrEP) care compromises the goal of HIV elimination. We investigated the proportion of LTFU and associated risk factors among men who have sex with men (MSM) enrolled in a PrEP demonstration project in Burkina Faso, Côte d’Ivoire, Mali, and Togo. CohMSM-PrEP, a prospective cohort study, was conducted between November 2017 and June 2021 in community-based clinics. MSM aged 18 years or older at substantial risk of HIV infection received a comprehensive prevention package, including PrEP and peer education. LTFU was defined as not returning to the clinic for six months. Associated risk factors were investigated using a time-varying Cox’s model. Of 647 participants followed up for a median time of 15 months, 372 were LTFU (57.5%). LTFU was associated with younger age (adjusted hazard ratio [95% Confidence Interval]; 1.50 [1.17–1.94]), unemployment (1.33 [1.03–1.71]), depression (1.63 [1.12–2.38]), and perceiving no HIV risk with stable male partners (1.61 [1.23–2.10]). Contacting peer educators outside of scheduled visits was protective (0.74 [0.56–0.97]). Our findings show that LTFU from PrEP care in West African MSM is a major challenge to achieving HIV elimination, but that the involvement of peer educators in PrEP delivery helps to limit LTFU by providing users with adequate support.
Published: 2022

47. Populations at risk for alveolar echinococcosis, France

Author: Piarroux, Martine, Piarroux, Renaud, Knapp, Jenny, Bardonnet, Karine, Dumortier, Jérôme, Watelet, Jérôme, Gerard, Alain, Beytout, Jean, Abergel, Armand, Bresson-Hadni, Solange, Gaudart, Jean, Surveillance Network, Francechino, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U912 INSERM - Aix Marseille Univ - IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Infections Parasitaires : Transmission, Physiopathologie et Thérapeutiques (IP-TPT), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Service de Santé des Armées, Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), service d'Hépato-gastro-entérologie, Hospices Civiles de Lyon-Hôpital Edouard Heriault, Service d'Hépato-gastro-entérologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Institut de Mécanique et d'Ingénierie de Bordeaux (I2M), Institut National de la Recherche Agronomique (INRA)-Université de Bordeaux (UB)-École Nationale Supérieure d'Arts et Métiers (ENSAM), Arts et Métiers Sciences et Technologies, HESAM Université (HESAM)-HESAM Université (HESAM)-Arts et Métiers Sciences et Technologies, HESAM Université (HESAM)-HESAM Université (HESAM)-Institut Polytechnique de Bordeaux-Centre National de la Recherche Scientifique (CNRS), Service des Maladies Infectieuses et Tropicales [CHU Clermont-Ferrand], CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Service d'hépatologie, CHU Etaing, Service de Santé des Armées-Assistance Publique - Hôpitaux de Marseille (APHM)-Aix Marseille Université (AMU)-Institut de Recherche pour le Développement (IRD), Laboratoire Chrono-environnement - UFC (UMR 6249) (LCE), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Hôpital Jean Minjoz, Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon), Service des Maladies Infectieuses et Tropicales, Hôpital Gabriel Montpied, Clermont-Ferrand, France, Service des Maladies Infectieuses et Tropicales, Hopital Gabriel Montpied, Clermont-Ferrand, France, Laboratoire Chrono-environnement (UMR 6249) (LCE), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Arts et Métiers Sciences et Technologies, HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Institut Polytechnique de Bordeaux-Centre National de la Recherche Scientifique (CNRS), Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale ( SESSTIM ), Institut de Recherche pour le Développement ( IRD ) -Aix Marseille Université ( AMU ) -ORS PACA-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Infections Parasitaires : Transmission, Physiopathologie et Thérapeutiques ( IP-TPT ), Institut de Recherche pour le Développement ( IRD ) -Aix Marseille Université ( AMU ) -Assistance Publique - Hôpitaux de Marseille ( APHM ) -Service de Santé des Armées-Université de Montpellier ( UM ), Laboratoire Chrono-environnement ( LCE ), Université Bourgogne Franche-Comté ( UBFC ) -Centre National de la Recherche Scientifique ( CNRS ) -Université de Franche-Comté ( UFC ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ), Centre Hospitalier Régional Universitaire de Nancy ( CHRU Nancy ), Institut de Mécanique et d'Ingénierie de Bordeaux ( I2M ), Institut National de la Recherche Agronomique ( INRA ) -Université de Bordeaux ( UB ) -Institut Polytechnique de Bordeaux-Centre National de la Recherche Scientifique ( CNRS ), Institut de Recherche pour le Développement (IRD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU), Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM), Aix Marseille Université (AMU) - ORS PACA - Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire Chrono-environnement (LCE), Centre National de la Recherche Scientifique (CNRS) - Université de Franche-Comté (UFC), Hospices Civiles de Lyon - Hôpital Edouard Heriault, Service d'Hépatogastroentérologie, CHU de Nancy-Brabois, Université Sciences et Technologies - Bordeaux 1 - Arts et Métiers ParisTech - Institut Polytechnique de Bordeaux - Centre National de la Recherche Scientifique (CNRS), Service d'Hépato-Gastro-Entérologie, CHU de Clermont-Ferrand - Hôpital d'Estaing, and Aix Marseille Université (AMU)
Subjects: Male, Rural Population, [MATH.MATH-PR] Mathematics [math]/Probability [math.PR], Veterinary medicine, communicable disease prevention and control, MESH : Retrospective Studies, MESH : Anthelmintics, Alveolar echinococcosis, 0302 clinical medicine, [STAT.AP] Statistics [stat]/Applications [stat.AP], MESH: Rural Population, [SDV.SPEE] Life Sciences [q-bio]/Public Health and Epidemiology, Medicine, MESH: Animals, [SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases, Anthelmintics, 0303 health sciences, MESH: Middle Aged, MESH: Echinococcosis, Hepatic, 3. Good health, MESH: Anthelmintics, agricultural workers diseases, alveolar echinococcosis, MESH : Endemic Diseases, Microbiology (medical), MESH : Albendazole, medicine.medical_specialty, Echinococcus multilocularis. epidemiology, Echinococcus multilocularis, Albendazole, lcsh:Infectious and parasitic diseases, 03 medical and health sciences, [SDV.EE.SANT] Life Sciences [q-bio]/Ecology, environment/Health, Humans, MESH : Middle Aged, Risk factor, MESH : Mebendazole, Retrospective Studies, MESH : Foxes, MESH: Echinococcus multilocularis, MESH: Humans, 030306 microbiology, MESH : Humans, lcsh:R, MESH: Adult, MESH: Retrospective Studies, Odds ratio, zoonoses, Relative risk, [SDE.ES] Environmental Sciences/Environmental and Society, MESH: Female, Demography, MESH: Liver, Endemic Diseases, MESH: Registries, Foxes, lcsh:Medicine, MESH : Echinococcus multilocularis, Risk Factors, MESH: Risk Factors, Epidemiology, MESH : Socioeconomic Factors, MESH : Female, Registries, rural health, [MATH.MATH-ST] Mathematics [math]/Statistics [math.ST], [STAT.ME] Statistics [stat]/Methodology [stat.ME], biology, Rural health, MESH : Adult, Middle Aged, MESH : Risk Factors, Mebendazole, Infectious Diseases, Liver, MESH: Endemic Diseases, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Female, epidemiology, France, [SDV.MP.PAR] Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology, Adult, [ SDV.MP.PAR ] Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology, Echinococcosis, Hepatic, MESH: Socioeconomic Factors, MESH : Male, 030231 tropical medicine, [MATH.MATH-DS] Mathematics [math]/Dynamical Systems [math.DS], parasites, MESH: Mebendazole, Echinococcosis, MESH: Albendazole, Animals, lcsh:RC109-216, [SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology, MESH : France, MESH: Foxes, business.industry, Research, MESH : Liver, Retrospective cohort study, biology.organism_classification, MESH: Male, MESH : Rural Population, MESH: France, Socioeconomic Factors, MESH : Animals, business, MESH : Echinococcosis, Hepatic, MESH : Registries
Abstract: International audience; During 1982-2007, alveolar echinococcosis (AE) was diagnosed in 407 patients in France, a country previously known to register half of all European patients. To better define high-risk groups in France, we conducted a national registry-based study to identify areas where persons were at risk and spatial clusters of cases. We interviewed 180 AE patients about their way of life and compared responses to those of 517 controls. We found that almost all AE patients lived in 22 départements in eastern and central France (relative risk 78.63, 95% CI 52.84-117.02). Classification and regression tree analysis showed that the main risk factor was living in AE-endemic areas. There, most at-risk populations lived in rural settings (odds ratio [OR] 66.67, 95% CI 6.21-464.51 for farmers and OR 6.98, 95% CI 2.88-18.25 for other persons) or gardened in nonrural settings (OR 4.30, 95% CI 1.82-10.91). These findings can help sensitization campaigns focus on specific groups.
Published: 2013

48. Diversity of attitudes towards complementary and alternative medicine (CAM) and vaccines: A representative cross-sectional study in France

Author: Jeremy K. Ward, Fatima Gauna, Michael J. Deml, Norah MacKendrick, Patrick Peretti-Watel, CERMES3 - Centre de recherche Médecine, sciences, santé, santé mentale, société (CERMES3 - UMR 8211 / U988 / UM 7), École des hautes études en sciences sociales (EHESS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut des sciences de la santé publique [Marseille] (ISSPAM), Institute of Sociological Research, Department of Sociology, University of Geneva, Department of Sociology, Rutgers University, Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille] (ORS PACA), Vecteurs - Infections tropicales et méditerranéennes (VITROME), and Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées [Brétigny-sur-Orge] (IRBA)
Subjects: [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, Health (social science), [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, History and Philosophy of Science, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, [SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology, [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology
Abstract: International audience
Published: 2023

49. Satisfaction with care in HIV-infected patients treated with long term follow up antiretroviral therapy: the role of social vulnerability

Author: M. Préau, C. Protopopescu, F. Raffi, D. Rey, G. Chêne, F. Marcellin, C. Perronne, J.M. Ragnaud, C. Leport, B. Spire, null the ANRS CO8 APROCO-COPILOTE Study, LabECD, Université de Nantes (UN), Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U912 INSERM - Aix Marseille Univ - IRD), Institut de Recherche pour le Développement (IRD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU), Centre hospitalier universitaire de Nantes (CHU Nantes), CHRU, Hospices civils, Epidémiologie et Biostatistique [Bordeaux], Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Raymond Poincaré [AP-HP], Hôpital Pellegrin, CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Modèles et méthodes de l'évaluation thérapeutique des maladies chroniques (U738 / UMR_S738), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Diderot - Paris 7 (UPD7), ORS PACA, Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Université Bordeaux Segalen - Bordeaux 2, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM), ORS PACA - Aix Marseille Université (AMU) - Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Nantes, Université Bordeaux Segalen - Bordeaux 2 - Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED) - Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Raymond Poincaré, Assistance publique - Hôpitaux de Paris (AP-HP) - Hôpital Raymond Poincaré - Université Paris Descartes - Paris 5 (UPD5), Laboratoire de Recherche en Pathologie Infectieuse, Université Paris Diderot - Paris 7 (UP7), Institut de recherche, santé, environnement et travail [Rennes] (Irset), École des Hautes Études en Santé Publique [EHESP] (EHESP) - Institut National de la Santé et de la Recherche Médicale (INSERM) - Université de Rennes 1 (UR1) - Université des Antilles et de la Guyane (UAG) - Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), and ANRS CO8 APROCO-COPILOTE Study Group
Subjects: Male, Health (social science), HIV Infections, Logistic regression, Cohort Studies, 0302 clinical medicine, Quality of life, Antiretroviral Therapy, Highly Active, Hiv infected patients, 030212 general & internal medicine, [SDV.MP.VIR] Life Sciences [q-bio]/Microbiology and Parasitology/Virology, Coinfection, Medical record, Disease Management, Life Sciences, Patient Preference, satisfaction with care, Professional-Patient Relations, Middle Aged, Hepatitis C, Quality Improvement, 3. Good health, side effects, Patient Satisfaction, Cohort, Female, 0305 other medical science, Clinical psychology, Adult, medicine.medical_specialty, Social Psychology, Drug-Related Side Effects and Adverse Reactions, Long term follow up, Medication Adherence, 03 medical and health sciences, Social support, satisfaction with physician, medicine, Medical Records, Problem-Oriented, Humans, 030505 public health, business.industry, Public Health, Environmental and Occupational Health, social support, quality of life, Family medicine, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Self Report, business, Social vulnerability, Delivery of Health Care
Abstract: International audience; The aim of this study was to determine factors associated with complete satisfaction with the care provided (satisfaction with physicians and satisfaction with services and organization) among HIV-infected patients followed-up in the French ANRS CO8 APROCO-COPILOTE cohort. Analyses focused on cross-sectional data collected during the ninth year of cohort follow-up. Satisfaction with care (Bredard & al, 2005), sociodemographic characteristics and behavioral data were collected using self-administered questionnaires, while clinical data were derived from medical records. Complete satisfaction with care was defined as being 100% satisfied. Two logistic regression models were used to identify predictors of (i) complete satisfaction with physicians (n=404) and (ii) complete satisfaction with services and organization (n=396). Sixteen percent of patients were completely satisfied with physicians while 15.9% were completely satisfied with services and organization. Being older and reporting fewer discomforting antiretroviral therapy (ART) side effects were factors independently associated with complete satisfaction with both physicians and services and organization. Strong support from friends and absence of hepatitis C (HCV) co-infection were independently associated with complete satisfaction with physicians, while strong support from one's family and comfortable housing conditions were independently associated with complete satisfaction with services and organization. Even after nine years of follow-up, social vulnerabilities still strongly influence HIV-infected patients' interactions with the health care system. Day-to-day experience with the disease, including perceived treatment side effects, appears to play a key role in the quality of these interactions. More attention should be given to patient satisfaction, especially for socially vulnerable patients, in order to avoid potentially detrimental consequences such as poor adherence to ART.
Published: 2011

50. O2-1 Improving diet and physical activity in older adults living at home: protocol for the ALAPAGE cluster randomized controlled trial

Author: Vinet, A, Bocquier, Aurélie, Dubois, Christophe, Verger, Pierre, Darmon, Nicole, EA4278 Laboratoire de Pharm-Ecologie Cardiovasculaire (LaPEC), Avignon Université (AU), Adaptation, mesure et évaluation en santé. Approches interdisciplinaires (APEMAC), Université de Lorraine (UL), Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Institut Hospitalier Universitaire Méditerranée Infection (IHU Marseille), Vecteurs - Infections tropicales et méditerranéennes (VITROME), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées [Brétigny-sur-Orge] (IRBA), Observatoire régional de la santé Provence-Alpes-Côte d'Azur [Marseille] (ORS PACA), Montpellier Interdisciplinary center on Sustainable Agri-food systems (Social and nutritional sciences) (UMR MoISA), Centre de Coopération Internationale en Recherche Agronomique pour le Développement (Cirad)-Institut de Recherche pour le Développement (IRD)-Centre International de Hautes Etudes Agronomiques Méditerranéennes - Institut Agronomique Méditerranéen de Montpellier (CIHEAM-IAMM), Centre International de Hautes Études Agronomiques Méditerranéennes (CIHEAM)-Centre International de Hautes Études Agronomiques Méditerranéennes (CIHEAM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Institut Agro Montpellier, and Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)
Subjects: Healthy diet, Physical activity, Older adults, Public Health, Environmental and Occupational Health, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Co-construction
Abstract: Background Adequate nutrition and regular physical activity (PA) are key elements in healthy aging. In France, behavioural interventions promoting healthy eating and PA in older adults consist mainly in collective workshops organised by pension and health insurance funds. After analyzing pre-existing workshops, we designed the co-constructed project ALAPAGE to improve these workshops and assess their impact on diet and PA. Methods ALAPAGE is a cluster randomized controlled trial; 60 collective workshops in southeastern France will be randomized in a 2:1 (intervention/control) ratio. We will recruit 900 autonomous older adults (? 60 years) living at home and will make specific efforts to recruit socially isolated and/or economically vulnerable people. In the intervention group, collective workshop period will include 7 sessions (1 session/week): 1 introductory, 4 diet and 2 PA (to teach principles of functional dual-task exercise focused on strength, flexibility and physical functioning). During the following 3-months, participants will be recommended to perform exercises as often as possible and will participate in post-workshop activities. The control group will first participate to other types of workshops and then to a diet and PA workshop (waiting-list design). Results The dietary practices (using experimental economics), physical activity (battery of field test and habitual PA), quality of life, and cost-effectiveness will be assessed at the first and last session, and 3 months later. Conclusion Results will guide decision-makers to organize actions and their dissemination. Transferability to other regions will be facilitated by the fact that key stakeholders involved in ALAPAGE belong to structured national networks.
Published: 2022

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

835 results on '"ORS PACA"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources